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Abstract: 
Pilot Study to Evaluate the Impact of an Educational Video about Melanoma 
on Knowledge and Behavior. Sepideh Bagheri, Jean Bolognia, Marianne Berwick. 
Department of Dermatology, Yale University, School of Medicine, New Haven, CT. 
Background: Given the growing worldwide incidence and mortality of melanoma, and a 
lack of cure at more advanced stages of the disease, much effort has focused on educational 
and screening interventions aimed at diagnosing lesions at earlier, potentially more curable 
stages. Skin self-examination (SSE) has received increasing attention as a means of 
complementing public screenings; however, to date, there have been no trials specifically 
aimed at promoting SSEs among targeted populations. 
Objective: In this pilot study, an educational video on melanoma was prepared to not only 
raise subjects’ awareness about melanoma epidemiology, but also prompt regular SSEs 
(including the use of a “buddy”). 
Methods: Of the 94 participants recruited, 86 completed the study: 33 melanoma, 33 
atypical nevus, and 21 control subjects. Each subject received a total skin examination by 
a physician and viewed the ten-minute video, in addition to completing pre- and a post¬ 
intervention questionnaires (on knowledge and SSE practices). 
Results: Of note, the melanoma and nevus groups had the highest knowledge scores, while 
the controls had the greatest improvement. The controls were as knowledgeable of 
melanoma risk factors (like red hair and blue eyes) as the melanoma and nevus subjects, but 
less knowledgeable about melanoma signs and symptoms. One of the greatest post¬ 
intervention changes related to awareness of such methods as the “buddy” system to examine 
. 
difficult-to-see areas. Other significant predictors of knowledge increase included the hair 
color, the objective (physician-determined) and subjective (self-reported) nevus counts, and 
the presence of atypical nevi. Regarding SSE practices, the melanoma and nevus subjects 
were significantly more likely to perform SSEs (at least once per year) as compared to the 
controls. However, there were no significant predictors of either “optimal'’ SSEs (defined 
as once per month to once every four months) or improved SSEs. 
Conclusion: Based on our results, a video on melanoma appears to be an excellent 
educational medium, as observed by the significant improvements in knowledge among the 
controls. However, more intensive and continuous interventions may be needed in order to 
affect behavioral change. 
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Cutaneous melanoma is the most aggressive of all skin cancers. It is a malignancy 
of melanocytes, the dendritic cells within the epidermis whose principal function is to 
synthesize melanin and distribute it to surrounding keratinocytes. The melanin serves 
several functions, including the protection of keratinocytes and melanocytes against 
ultraviolet radiation [110, 182]. 
One of the most alarming features in the epidemiology of melanoma is the dramatic 
rise in its worldwide incidence, along with a more modest rise in the associated mortality. 
In 1994, an estimated 32,000 new cases of melanoma and 6900 (4300 men and 2600 women) 
deaths due to melanoma were reported in the United States alone [6, 38], 
From the 1960's to the 1980's, the incidence of melanoma increased by 3.5 times in 
men and 4.6 times in women [129]. Moreover, the incidence of melanoma appears to be 
doubling every one to two decades [43, 115, 230, 231, 253, 333, 335]. (Such trends are 
cause for even more concern given that the true incidence rates are probably under-estimated 
with the ever-increasing trend toward out-patient diagnosis and treatment, resulting in 
incomplete registration [36, 174, 183, 343]). For instance, the Connecticut Tumor Registry, 
which has been tracing the number of melanomas diagnosed since 1935, quoted an age- 
adjusted melanoma incidence of 1.0/105/year for its first 5 years; this incidence had risen to 
12.4/105/year by 1989 [355], These trends have been corroborated by the cancer registries 
of Denmark [166], other Scandinavian countries [43, 230, 231, 333, 335], Australia and New 
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Zealand [37, 47, 107, 132, 215], Canada [120], Europe [34, 123, 238, 265], and additional 
States within the United States [50, 129, 268], including Hawaii [156]. 
Melanoma mortality rates have been rising as well, although not as rapidly as the 
incidence rates [262]. This has been reported by countries such as the United States, the 
United Kingdom, Canada, Sweden, Australia, New Zealand, and Japan [102, 115, 202, 253]. 
In the United States, melanoma mortality has had a faster rate of increase than that for any 
other cancer (except for lung cancer in women) [115, 246]. Mortality rates have been 
increasing by approximately 2-3% annually in Caucasian populations [355], However, two 
recent studies from the United States have projected a future downward trend in melanoma 
mortality [106]. Using birth cohort analysis of melanoma cases and deaths from the 
Connecticut Tumor Registry, one projected a downward trend in melanoma mortality for 
both men and women [306]. Using SEER and National Center for Health Statistics data 
(1973-1984), the other projected that the current upward trend in age-adjusted mortality rates 
will taper off, leading to a maximum death rate in the near future, followed by a reduction 
in melanoma deaths by the second decade of the 21st century [313]. Cohort analyses of 
mortality rates in the United States revealed the highest mortality rates among men born 
around 1950, and among women born between 1930 and 1950, while demonstrating lower 
mortality rates among later-bom cohorts [306]. Given the continued rise in incidence rates, 
the investigators in this study attributed these findings to earlier detection. In Canada, the 
mortality rates among women continued to rise through the mid-1980's, showing some 
decline thereafter; however, among men, the upward trend in mortality has continued [105]. 
In Sweden, melanoma mortality rates had been rapidly rising since 1953 in all but men under 
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50 years of age, whose rates had shown no increase. Since 1978, however, the mortality 
rates have been stabilizing among Swedish women, with slowing of the rate of increase 
among men [336]. In Scotland, melanoma mortality rates have been declining among 
women since 1987, with no change in the rate among men [225], This trend has been 
attributed to the intensive public education campaigns, which has resulted in increased 
proportions of thinner melanomas among women. 
Given the growing threat of melanoma as a public health hazard and our increased 
knowledge regarding its risk factors, education would represent an obvious means for its 
containment, through both primary prevention (i.e., sun exposure precautions), and 
secondary prevention (i.e., early detection) [144], To date, most efforts have focused on 
earlier diagnosis, in hopes of intervening at a potentially more curable stage in the cancer’s 
natural history, i.e., the precursor or radial growth phase.2 In this regard, melanoma holds 
the unique advantage of being amenable to easy detection due to its visible cutaneous 
location. 
Early detection assumes great importance when one considers that the Breslow depth 
(measured in millimeters from the stratum granulosum to the lower most portion of the 
tumor) is the single-most important prognostic indicator for survival [45], There is a direct 
correlation between the tumor thickness and the probability of developing metastases. 
Therefore, thinner melanomas are associated with significantly higher survival rates: lesions 
less than 0.76 mm in Breslow depth are associated with five-year survival rates of 93% to 
100%, as compared to less than 50% survival rates for lesions greater than 3 mm in Breslow 
depth [14, 19]. Also, those with localized disease have long-term survival rates of 75% to 
, 
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over 80%, as compared to only 15%-20% for patients with regional spread, and rare survival 
in those with distant metastases (with median survivals of around 6 months) [355]. These 
data have served as rationale for advocating skin self-examination (SSE) in the general 




In preceding decades, much effort was concentrated on delineating possible risk 
factors for the development of melanoma, with the dual goals of not only identifying high 
risk groups as targets for early intervention through screening programs, but also 
disseminating knowledge about the risk factors through public education campaigns. To 
date, the following have been identified as melanoma risk factors: (1) melanocytic nevi—the 
presence of either atypical nevi or greater-than-average numbers of common acquired 
melanocytic nevi; (2) phenotypic characteristics—color of eyes, hair, and skin type (tendency 
to bum and inability to tan); (3) family history of melanoma; (4) personal history of 
melanoma; (5) history of sunburns or chronic sun-damage (as in patients with lentigo 
maligna melanoma); and (6) the presence of precursor lesions such as congenital nevi. 
I. Nevi: 
Over the past decade, there has evolved growing awareness of the association 
between melanocytic nevi and melanoma. Case-control studies report that the presence of 
either atypical nevi or higher-than-average numbers of common acquired melanocytic nevi 
to be the strongest, independent risk factors for melanoma [109]. 
Common Acquired Melanocytic Nevi (CAMN) versus Atypical Nevi: CAMN are 
benign neoplasms of melanocytes, with a clinical and histologic appearance, distribution, and 
developmental history which differs in several ways from that of atypical nevi. (As in any 
biological system, however, there is some overlap). Clinically, the initial CAMN lesions 
present as 2-4 mm macules (or slightly elevated papules), with a symmetric shape, well- 
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circumscribed borders, and a uniform tan to dark brown color. At its initial developmental 
stage, it is termed a “junctional nevus”, characterized histologically by the formation of 
melanocytic nests-confined to the dermo-epidermal junction—at the tips of the rete ridges, 
and variable lentiginous hyperplasia. Junctional nevi can remain completely stable over 
time, or gradually undergo a lateral expansion phase, during which they may enlarge to a 
maximal size of 4-6 mm. 
Again, at the completion of this lateral expansion phase, they may remain stable, or 
begin a vertical growth phase, during which the melanocytes migrate into the dermis, and 
thereby evolve into “compound nevi”. Clinically, compound nevi are distinguished from 
junctional nevi by their morphology as 1-7 mm, symmetrical, well-circumscribed, tan-brown 
papules. Their elevation is due to the symmetric dermal invasion. Meanwhile, compound 
nevi display all the histologic features of junctional nevi, in addition to the formation of 
melanocytic nests and cords within the dermis. 
With time, these nests and cords undergo a maturation process, whereby they 
penetrate deeper and deeper into the dermis and its underlying connective tissue while at the 
same time progressively losing their epidermal components [91,216, 252], At its extreme, 
this process leads to the formation of “dermal nevi”. Clinically, dermal nevi appear as 2-7 
mm pink or skin-colored papules, and histologically, they are characterized by nevus cells 
which are completely confined to the dermis, with only mature intradermal melanocytic nests 
and cords. Moreover, by this later developmental stage, the melanocytes have frequently lost 




In their anatomic distribution, CAMN tend to primarily occur on sun-exposed areas 
of the body, such as the upper trunk and the extensor surfaces of the upper extremities. 
CAMN are absent at birth, first appearing on the skin during infancy and early childhood, 
gradually growing in both number and size through to middle adult life. The average 
individual develops an estimated 15-30 nevi by early adulthood [254], but this number 
gradually declines in later years due to the natural regression of CAMN in late adulthood [88, 
216 252, 254], 
In contrast, atypical nevi (AN) are neoplasms of melanocytic origin, with clinical and 
histologic characteristics intermediate between those of CAMN and melanoma [56, 88, 141, 
142, 194, 286, 287, 290]. Clinically, they are characterized by their larger size (frequently 
greater than 5 mm in diameter, sometimes up to 12 mm), asymmetric shape, notched or ill- 
defined borders, uneven or cobblestoned surface (with the papular component frequently 
embedded within the macular portion), and variegated tan-red-brown color [350]. They are 
frequently distinguished by an inflammatory component, as evidenced by a pink hue, either 
at the periphery or throughout. Histologically, atypical nevi are lentiginous junctional or 
lentiginous compound nevi with architectural disorder, as evidenced by scattered 
melanocytes and disarrayed nests, with bridging of adjacent nevus nests, formation of nests 
at rete edges or in inter-rete spaces (as opposed to the tips of the rete ridges only), and 
expansive nests which may focally erode upwards into the epidermal layer. The individual 
nevus cells can display cellular atypia, as manifested by enlarged nuclei, angulated contours, 
dense hyperchromasia, and at times, an over-abundant yet coarsely-granulated cytoplasm. 
Other histologic components of an atypical nevus include stromal change: lamellar 
, 
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fibroplasia, vascular proliferation, melanin pigment incontinence, and a patchy lymphocytic 
infiltrate [18, 59, 252]. Here, erythema, nevus size, and border irregularity are the strongest 
clinical correlates of histologic atypia [18]~usually classified as either mild, moderate, or 
severe, where mild is insignificant and severe is significant, as it borders on melanoma in situ 
[350]. Although the lesions may remain stable over time, or regress, in general, the degree 
of atypia serves as a marker for the risk of malignant transformation, which may be heralded 
by the clinical signs of increased size, asymmetry, irregularity, or color variegation, scaling, 
crusting, bleeding, and sensations like tingling, itching, and pain [350]. 
In their distribution, atypical nevi mimic CAMN in that they also primarily occur 
sun-exposed areas such as the upper trunk and the extensor surfaces of the upper extremities; 
however, they differ from CAMN in that they also appear on doubly-shielded, non-sun- 
exposed areas such as the genitals, breasts (in women), scalp, and buttocks [195]. 
Atypical nevi are also distinguished from CAMN by their unique developmental 
history. Like CAMN, atypical nevi are absent at birth [141,216]. At approximately 5 to 8 
years of age, affected individuals begin to develop an increased number of morphologically 
normal nevi as well as a few larger nevi that are often located on the scalp or upper trunk. 
At puberty, these nevi may undergo significant changes in number, size, shape, and 
pigmentation. Although, like CAMN, individual lesions may regress in later years, unlike 
CAMN, new lesions may continue to develop throughout life, such that their total count may 
never decrease [16, 350]. 
Common Acquired Melanocytic Nevi (CAMN) and Melanoma: In the last two 
decades, there has been a growing awareness of CAMN as determinants of melanoma risk. 
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In biopsy specimens of cutaneous melanoma, remnants of junctional and compound nevi 
have been observed in histologic contiguity with the malignant cells. Reports of the 
frequency of this phenomenon have ranged anywhere from 18% to 72%, with estimates in 
the 30% to 50% range being most common [33, 56]. In a recent review, for instance, more 
than 50% of primary melanomas were in histologic contiguity with a precursor nevus, and 
this percentage rose to 64% when only thin tumors (<1.5 mm), with a lower likelihood of 
obliteration of the pre-existing nevus, were considered [309]. Moreover, as many as 80% 
of melanoma patients report changes in a pre-existing mole [88]. (It is important to note, 
however, that patients can mistakenly confuse an early melanoma arising de novo with a 
changing mole, due to their similar clinical morphology). 
A number of case-control studies have shown the presence of greater-than-average 
CAMN counts to be the single most important determinant of melanoma risk, with greater 
risks with higher total CAMN counts [144, 361 ] (Table 1). The magnitude of melanoma risk 
associated with increased numbers of CAMN has varied considerably, ranging from 5 to 65 
[361]; this wide range is partially due to differences in the definition of CAMN, the areas of 
the body examined, and the method used to count the CAMN. A review of nine case control 
studies examining the relation between CAMN and melanoma risk found an extreme risk of 
melanoma (RR=63.8) in subjects with more than 50 nevi greater than 2 mm in diameter, with 
even greater risks in the presence of clinically atypical nevi [329, 330]. In other studies, 
excess numbers of arm nevi [100, 135, 138, 161, 329] or total body nevi [82, 158, 200, 258, 
303, 329, 330, 356] were associated with an at least 3-fold increase in melanoma risk [27, 
68, 82, 86, 100, 108, 135, 138, 158, 159, 161, 200, 258, 280, 303, 320, 328, 329, 330, 356], 
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The Western Australia Melanoma Study reported a multi-variate odds ratio of 10.35 in the 
presence of 10 or more palpable nevi on the arms [161], while the Queensland Melanoma 
Study documented a multi-variate odds ratio of 30.1 for the presence of any arm nevi [135, 
161] (Table 1). 
Multiple case control studies have noted a gradient in melanoma risk as a function 
of the nevus count, with increased risk with higher nevus counts [99, 135, 159, 200, 328, 
330], In such studies, the estimated melanoma risk for the highest mole categories has 
ranged from 9.8 (for greater than 100 CAMN on the entire body) [159] to 133.4 (for the 
presence of >40 nevi on the trunk) [200][ 109, 135, 143, 159 356, 200, 330] (Table 1). The 
San Francisco Melanoma Study, counting nevi greater than 2 mm in diameter on the entire 
body area, documented the following gradient in melanoma risk: 0-10 nevi, RR=1.0, 11-25 
nevi, RR=1.6; 26-50 nevi, RR=4.4; 51-100 nevi, RR=5.4; > 100 nevi, RR=9.8 [159] (Table 
1). A population-based melanoma study in Denmark reported similar results [259]. Here, 
the melanoma risk associated with the nevus count was found to be independent of all other 
risk factors, accounting for an estimated 29-79% of all melanomas [304], 
Given the significance of CAMN as not only predictors of melanoma risk, but also 
lesions from which melanoma may arise, much effort has been devoted to determining their 
etiology, so as to delineate the links common to the pathogenesis of CAMN and melanoma, 
and thereby possible means of prevention. At present, the etiology of CAMN is wrought 
with controversy. Some studies suggest that the total nevus count is determined genetically 
[142], while others implicate sunlight and sun-exposure (as contributors to their phenotypic 
expression) as major determinants [192]. 
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The distribution of nevi on the body has been used to support the role of sunlight and 
sun-exposure as determinants of the total nevus count. For instance, both melanocytic and 
atypical nevi tend to occur in greater proportions on the lateral, more sun-exposed aspects 
of the arm, as compared to the medial, more sun-protected surfaces [192, 193]. However, 
one study refuted such a correlation between total numbers of nevi, whether benign or 
atypical, and ultraviolet exposure [271]. 
There is also evidence to support the role of sunlight in the etiology of CAMN, and 
therefore (possibly) melanoma: body sites with higher mole counts—which are also sites of 
greatest intermittent sun exposure, as explained above—have been shown to be preferential 
sites for the development of melanoma [121, 200]; meanwhile, sun-shielded regions such as 
the genitals, breasts (in women), scalp, and buttocks have shown the lowest incidences of not 
only melanoma, but also (melanocytic and atypical) nevi [5, 121, 167, 192, 193, 200, 270]; 
and migrant studies correlate higher nevus counts with a younger age at the time of migration 
to a sunny climate [4, 139], Such data implicate the presence of common stimuli in the 
pathogenesis of CAMNs and melanoma. Either UV radiation induces the expression of 
(melanocytic and atypical) nevi which later act as targets for other promoters, or UV 
radiation acts as a promoter on these unstable target lesions, i.e. nevi, to induce melanoma 
[111,361], 
Atypical (AN) and Melanoma: From an historic standpoint, interest in atypical nevi 
(AN) as a risk factor for melanoma dates back to 1976, at which time a National Cancer 
Institute (NCI)/University of Pennsylvania (UPenn) team started to examine a melanoma- 
prone kindred, known as Family K. The presence of numerous clinically atypical nevi on 
* 
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the body of many members of this family, with both morphologic [278] and histologic [55] 
similarities to early cutaneous melanoma ignited interest in the possible association between 
the two [201]. Thus, it was in the context of melanoma-prone kindreds that the association 
between atypical nevi and melanoma was first defined [141]. Later, the NCI/UPenn group 
conducted a prospective surveillance of 14 such melanoma-prone kindreds, and in the 
process, charted the development of new cutaneous melanomas in only those family 
members with AN—i.e., none developed amongst relatives with clinically normal skin [141, 
142]. In these cases, the histologic contiguity of the melanoma lesions with atypical nevi 
demonstrated that, in at least the familial melanoma setting, atypical nevi serve as not only 
markers of increased risk of de novo melanoma formation, but also the structural precursors 
from which melanoma may arise [141, 350]. Another study following a larger cohort of 
families, for a longer period, obtained similar results [144, unpublished]. 
Later, it was recognized that atypical nevi also occur in melanoma patients without 
a family history of melanoma [87], and even in individuals with neither a personal nor a 
family history of melanoma [74]. Such findings led to the recognition that atypical nevi 
(AN) can occur in either familial or sporadic settings. The familial atypical nevus-melanoma 
syndrome is characterized by a increased numbers of CAMN, along with the presence of a 
multitude of atypical nevi as compared to the average population. Affected individuals are 
considered to have at least two blood relatives with both atypical nevi and a prior history of 
melanoma. In contrast, the sporadic cases may or may not have numerous CAMN, and may 
involve only a few AN [350]. These findings have stimulated interest in the epidemiology 
of atypical nevi, as well as their possible relationship with CAMN. 
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Epidemiologic studies have estimated that atypical nevi affect approximately 5% of 
the white population, of whom 5% will develop melanoma over their lifetime [17]. 
Moreover, atypical nevi increase melanoma risk in both the familial and the sporadic 
settings, appearing on 35% of all melanoma patients, and on 100% of all familial melanoma 
patients [17]. Careful histologic studies have revealed remnants of atypical nevi at the 
margins of invasive melanoma lesions in about one third of unselected melanoma cases [33]. 
Furthermore, case-control studies involving skin examinations have yielded AN prevalence 
estimates ranging from 6% to 55% (34% median) among melanoma cases, and from 0% to 
17% (median 7%) among controls [27, 68, 74, 108, 147, 149, 159, 258, 304, 328]. Similar 
estimates were attained upon excluding all subjects with a family history of melanoma [149, 
304]. 
Linkage studies have revealed the familial atypical nevus-melanoma syndrome to 
follow an autosomal dominant inheritance pattern, with variable penetrance and expressivity 
[29, 141, 142, 176, 221]. The familial atypical nevus-melanoma syndrome accounts for an 
estimated 5% to 10% of all cases of melanoma [91], and affected individuals are at 100% 
lifetime risk of developing melanoma by age 70 [142, 194]. In this setting, not only do 
melanomas occur at a younger age than in the general public [221], but also the survivors are 
at high risk for additional primaries [142, 257]. Indeed, in the NCI study of the 14 atypical 
nevus-melanoma syndrome kindreds, the prospective relative risk of melanoma among 
family members with no prior melanoma was 150, while the relative risk for melanoma 
among family members with a prior melanoma was 500 [142]. Also, this study revealed that 
melanomas developed in only family members with atypical nevi. Such findings signal the 
’ 
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need for close lifelong surveillance of affected individuals by a dermatologist [142, 257]. 
And, in fact, prospective studies entailing careful longitudinal surveillance of such 
individuals have documented a shift in the Breslow depth of newly diagnosed melanomas 
toward thinner, better-prognosis lesions [141,237, 344], Such interventions may ultimately 
affect the melanoma mortality rates in these populations. 
Similar estimates of melanoma risk in the sporadic, non-familial AN setting were 
controversial for some time, mainly due to the lack of definitive histopathologic criteria for 
the evaluation of the involved specimens. Recent studies, however, have shown acceptable 
degrees of interpathologist concordance following adherence to the criteria for both 
architectural and cytologic atypia [35, 59]. The World Health Organization has documented 
a concordance rate of 88% [59], while a Dutch study has reported a sensitivity of 92%, a 
specificity of 98%, a positive predictive value of 89%, and a negative predictive value of 
98%, using the outlined criteria [321]. 
Subsequent to these reports, an estimated 29% to 49% of non-familial melanomas 
were attributed to AN as a risk factor [304]. Furthermore, reported relative risks of 
melanoma in the setting of non-familial atypical nevi have ranged between a 7-fold increased 
risk, as based on estimates [196], and a 22-fold increased risk, as based on prospective 
measurements [295], as compared to controls. (The latter value was considered unstable due 
to the limited number of individuals enrolled in the study: 281 subjects with non-familial 
AN and no personal history of melanoma were followed over 27 months, during which time 
3 in situ melanomas and 1 invasive melanoma were detected, representing a 16-fold 
increased risk of invasive melanoma [295]. Nonetheless, this study was of critical 
’ 
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importance, in that it unequivocally documented the occurrence of both in situ and invasive 
melanomas in subjects with non-familial AN, thereby signaling the need for lifelong 
surveillance in this population.) 
Independent studies aimed at discerning the relationship between AN and CAMN 
have reported not only higher CAMN counts among subjects with AN [149, 159, 258, 305], 
but also higher AN counts among subjects with increased numbers of CAMN [258, 266, 
302], Furthermore, analyses aimed at separating the contribution of these two classes of nevi 
to the overall risk of melanoma suggest them to be independent risk factors [305]. Notably, 
these studies verify the interesting clinical observation that these independent (though 
critically significant) risk factors often occur in the same individuals [159]. 
II. Phenotypic Characteristics: 
The variation in melanoma rates by race and pigmentary skin characteristics is well- 
established. Melanin, the pigment whose form and concentration determines skin type and 
skin color, protects the melanocytes’ DNA from the damaging effects of ultraviolet radiation 
[297]. Given that melanocytes contain little melanin themselves, they are normally protected 
from UV radiation by the melanin in the keratinocytes surrounding them. This protection 
is less efficient in fair-skinned individuals, who have lower concentrations of melanin, as 
compared to more pigmented individuals [91]. Moreover, molecular studies have revealed 
red-haired individuals to have pheomelanin [264], a form of melanin which exacerbates the 
effects of UV radiation through the generation of potentially genotoxic and mutagenic free 
radicals [90,264], Therefore, it is not surprising that the degree of skin pigmentation directly 
correlates with the risk of melanoma [297], 
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Case-control studies have identified a cluster of phenotypic traits, such as blue or 
green eyes, red or blond hair, light complexion, freckles, “poor tanning ability”, and a 
“tendency to sunburn” that are associated with an increased risk of melanoma [109, 161, 
240]. Moreover, it appears that the entire cluster of traits (as a whole) is more important than 
any single trait alone. And as these phenotypic traits are determined genetically, the risk of 
melanoma also becomes partially defined by genetic factors [188]. 
A skin classification scheme separates whites into four groups on the basis of their 
“tendency to bum” and “inability to tan”. Skin phototypes I and II bum or develop a light 
tan, respectively, whereas skin phototypes III and IV develop a medium or dark tan, 
respectively. Case control studies from Europe, the United States, Canada, and Australia 
have established a 2-3-fold increase in melanoma risk with skin phototypes I and II [63, 98, 
260, 353, 364]. Other studies have documented a two-fold increase in melanoma risk among 
Caucasians with “fair” skin, as compared to those with “olive” skin [27, 98, 131, 135, 138, 
161]. Meanwhile, for all skin types, melanoma patients have increased light sensitivity, as 
evidenced by the significantly lower minimal erythema dose of their skin, as compared to 
controls [22]. A review of case-control studies revealed the “inability to tan” to be a 
significant risk factor in 15 of 16 studies, and the “tendency to sunburn” to be a significant 
risk factor in 21 of 24 studies [109]. 
Freckling, as a marker for the “inability to tan” in response to longterm sun exposure, 
has been associated with a two-fold increase in melanoma risk [27, 78, 98, 131, 135, 138, 
161, 280], One study, which documented a 29-fold increase in melanoma risk in the 
presence of both CAMN and freckles, as compared to when both traits were absent [138], 
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postulated a possible association between CAMN and sun-induced freckles. The same study 
quoted a 51-fold increase in melanoma risk in the presence of both high nevus counts and 
a tendency to sunburn (and not suntan), as compared to when both traits were absent. Upon 
adjusting for total lifetime sun exposure, this study found a relative risk of 30 for high nevus 
counts, 5.9 for red hair, and 3.5 for the tendency to sunburn [138]. 
Skin characteristics such as the “tendency to burn” and the “inability to tan” appear 
to be independent of such melanoma risk factors as nevi and “excessive” sun exposure [100, 
135, 138]. Moreover, the tendency to burn easily and tan poorly is a stronger predictor of 
melanoma risk than the actual frequency of sunburns recalled; also the increased risk of 
heavy vacation and recreational sun exposure appears to be independent of skin pigmentation 
and reaction to the sun [98, 133, 163]. There also appears to be no clear relationship between 
(recalled) anatomical sites of sunburns and anatomic sites of melanoma—this may be due to 
recall bias [138]. 
In regard to other phenotypic features, the literature commonly reports relative risks 
of 2 to 4 in association with blond and red hair [27, 131, 135, 161, 280], although one study 
attributed a relative risk of 74 to blond (as compared to brown or black) hair [23]. Many 
studies have found red hair to be the strongest phenotypic risk factor for melanoma [27, 97]. 
As mentioned before, the melanocytes of red-haired individuals have been documented to 
contain pheomelanin, a form of melanin believed to exacerbate the effects of UV light by 
generating free radicals which cause mutagenesis [91, 264]. Also, case-control studies have 
reported 1.5- to two-fold increased risk of melanoma in association with blue, green, gray, 
and hazel eyes [27, 131, 135, 161, 280]. 

18 
III. Family History of Melanoma: 
Studies have documented a strong and statistically significant association between 
the risk of melanoma (RR=5) and a positive family history of melanoma [135, 142, 161, 
194,289,290], This risk appears to be independent of such inherited (and confounding) risk 
factors as pigmentation and nevus count, although these may still play a role. In one study, 
the risk of melanoma (in the presence of a positive family history) was unrelated to the 
degree of closeness of the affected relative—i.e., it made no difference whether the melanoma 
occurred in a first- or second-degree relative [138]. However, in other studies, the 
association between melanoma risk and a positive family history disappeared with regression 
analysis, suggesting that the increased risk relates more to phenotypic characteristics, sun- 
exposure habits, [134, 138] and a propensity for higher nevus counts [87], Meanwhile, those 
with an affected first-degree relative have a melanoma relative risk of 2 to 10 [84, 135, 161, 
319], 
IV. Personal History of Melanoma: 
Individuals with a prior history of melanoma are at a significantly high risk for 
additional primaries; however the estimates of this risk have varied greatly, from a five-fold 
to a nine-fold increased risk [161, 339]. The most accurate estimate has been derived from 
a Connecticut study which followed a population of 4693 individuals with a diagnosis of 
melanoma for the development of subsequent primaries from 1935 to 1982 [339], In this 
population, 30 second primaries were detected, translating into an overall relative risk of 8.5; 
however, there was a significantly higher relative risk of 23 for those less than 40 years of 
age at the time of the first melanoma diagnosis. Another follow-up study of 384 consecutive 
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melanoma patients at the MD Anderson Hospital during 1969-1970 documented relative 
risks of 22 and 45 for second primaries—with the variance in the documented relative risks 
depending on the reference population used to generate the expected number of melanomas 
[144, unpublished]. Moreover, the diagnosis rate of second primaries is highest within one 
year of the original diagnosis (RR=24), but continues to remain substantially elevated long 
afterward [339]. These figures help identify a group at high risk for melanoma, which would 
benefit from preventive and interventional measures [144], 
V. Sunlight and Ultra-Violet (UV) Radiation: 
Retrospective case-control studies, epidemiologic studies on variations in melanoma 
as a function of race, phenotype, latitude of residence, migration (and age at the time of 
migration), body site distribution (of both melanomas and CAMN), occupation and 
socioeconomic status, and studies of melanoma in the setting of xeroderma pigmentosum and 
lentigo maligna melanoma have all helped document a role for sunlight and UV radiation in 
the pathogenesis of melanoma [181, 188]. 
Latitude Studies: Worldwide latitude gradients in melanoma incidence and mortality 
provided the first crude evidence for the role of sunlight in the etiology of melanoma [181]. 
Studies of melanoma incidence among Caucasians in five continents have documented an 
inverse relationship between melanoma incidence and latitude, and therefore, solar UVR 
exposure. This relationship is roughly linear up to a 50-degree latitude, and parabolic 
Thereafter [251]. Others have described this relationship as a quadratic equation [251]. 
Specifically, in nations with homogeneous, predominantly fair-skinned populations, 
as in Australia, North America, England, Wales, Norway, and Sweden, melanoma incidence 
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and mortality rates increase with proximity to the equator [85, 91, 93, 96, 203, 204, 221, 
251]. In Norway, the melanoma incidence is three times higher in the southern areas, as 
compared to more northern areas [229, 230]. In the United States, the melanoma rate among 
Connecticut residents was 3 times lower than that of Arizona residents (9 versus 26 per 105) 
[311]. Queensland, Australia has the highest worldwide melanoma incidence, at 30.9 per 105 
men and 28.5 per 105 women, as compared to that of Connecticut, at 8.4 per 105 men and 7.7 
per 105 women during 1978-1982 (all rates per year). The Queensland rates are four times 
higher than the U.S. rates—which are, in turn, double the Canadian and triple the U.K. figures 
[228,251,294, 358]. 
However, not all areas demonstrate consistent latitude gradients. For instance, the 
rates for Scandinavian countries are higher than those of Mediterranean countries [181]; and 
Finland and Western Australia lack such a latitude gradient [164], Such findings re¬ 
emphasize the important interplay between sunlight and such factors as sex, age, ethnic and 
phenotypic heterogeneity, customs, socioeconomic status, geography and climate, vacation 
habits, and migration effects [5, 164, 212]. 
Another geographic factor related to latitude that has received considerably less 
publicity is altitude. With the same logic, high altitude locales should experience higher 
melanoma rates given their greater UV radiation exposure [181]. This might explain why 
Tucson, Arizona, a southern city with an elevation of 2400 feet and a UVB intensity 4% 
higher than that of a site at sea-level but the same latitude, has one of the highest U.S. 
melanoma rates [311]. 
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Racial Differences: The geographic variation in melanoma incidence largely derives 
from an interplay between ethnic composition and latitude, the former an indicator of sun 
sensitivity and the latter an indicator of ultraviolet flux, and therefore, the intensity of sun 
exposure. The ethnic and racial composition of a population influences its susceptibility to 
melanoma through phenotypic features such as the a tendency to burn, the inability to tan, 
and hair and eye colors [355]. The melanin concentration in the keratinocytes overlying the 
melanocytes determines their (the melanocytes’) degree of protection from the harmful 
effects of UVR and its free-radical by-products. Also, dark-skinned individuals tend to have 
lower total nevus counts as compared to fair-skinned individuals [318]. 
The contribution of latitude, and hence sun exposure, to the development of 
melanoma has been differentiated from that of ethnicity by comparing melanoma rates in 
similar ethnic groups residing at different latitudes, such as the white populations in the 
United Kingdom versus Australia, and those within the United States, Canada, Australia, and 
Scandinavia [203, 355]. Studies have also compared melanoma rates in various ethnic 
groups within the same geographical region—and therefore, the same environmental 
exposures. From this perspective, investigations on the epidemiology of melanoma in the 
United States have been most interesting, given that it is a geographically unique area with 
widely divergent racial populations living in close proximity, not only exposed to the same 
environmental risk factors for melanoma, but also covered by the same population-based 
cancer registries—thereby facilitating the comparison of trends. The Surveillance, 
Epidemiology, and End Results (SEER) program is the broadest such registry in the United 
States, combining nine population-based registries that together cover approximately 10% 
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of the entire population [363]. According to the SEER, the 1987-1988 melanoma incidence 
was 10.9/105/year for whites and 0.9/105/year for blacks [294], Meanwhile, the 1972-1982 
Los Angeles County registry incidence rates for Anglos, Hispanics, and African-Americans 
(per 105/year) were 12.1, 3.3, and 1.1 among men, and 10.0, 3.6, and 1.0 among women, 
respectively [223], Similarly, for the years 1978-1981, the SEER registry quoted the 
following rates (per 105/year) in various regions: in New Mexico, 12.1 and 1.7 among 
Anglos and Hispanics, respectively; in San Francisco, 10.0 and 1.0 among whites and blacks, 
respectively, and <1.0 among the Chinese, Japanese, and Filipinos; and in Hawaii, 23.0 
among whites, but only 1.7 among Japanese-Hawaiians [165]. Earlier data from Hawaii 
[155, 156], Texas [222], South Africa [145], Germany [123], Puerto Rico [28, 345], and 
western Canada [98] have reported similar trends. Thus, in the United States, the risk of 
melanoma is 8-19 times higher in whites as compared to blacks [1,279, 160]. Similar trends 
are reported worldwide. Meanwhile, a 1986 survey of 614 U.S. hospitals found 98% of the 
4545 melanoma cases to have occurred in a white or Caucasian individual [12]. 
Of note, when melanoma does develop in blacks and Asians, populations with 
normally low incidences of melanoma, it has a predilection for subungual and palmoplantar 
surfaces, and mucous membranes, which are relatively sun-protected areas secondary to 
either their location, or their thick overlying stratum comeum [71, 73, 113, 127, 145, 202, 
213, 279, 326]. The high relative frequency of such melanomas in these groups is precisely 
due to the relative absence of melanomas at other sites in these populations; the absolute 
incidence of palmoplantar and subungual melanomas varies little among races [31, 63, 102, 
294,314, 324, 345], 
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Given that incidence rates are highest among whites, it is not surprising that mortality 
rates are also highest among whites. In the United States, during the years 1987-1988, the 
overall mortality (per 105/year) was 2.4 among whites and 0.4 among blacks [294]. 
However, case fatality rates are much higher among blacks as compared to whites [294]. 
Migration and “Critical Period” Studies: Migration and “critical period” studies 
have attempted to not only differentiate the roles of environmental and genetic factors in the 
etiology of melanoma, but also delineate specific childhood events that increase melanoma 
risk later in life [65, 160, 250], Migration studies within the United States [223, 352] and 
within Australia and New Zealand [65, 160, 250], as well as those of immigrants from 
Europe to Israel [2] and from the United Kingdom to Australia [160] have all shown higher 
rates of melanoma in immigrants to sunnier climates, as compared to genetically similar 
populations remaining in the native homelands. Also, the melanoma risk appears to increase 
with earlier arrival and longer residency in the new country, such that it eventually 
approaches that of life-long residents in the sunnier climate. Australian investigators have 
observed an increasing melanoma risk among immigrants to the sunny climate of Western 
Australia with increasing duration of residence (especially if they have resided there for more 
than 40 years [138]) [163]. However, as compared to native-born Australians, these 
immigrants are at a substantially lower overall risk for melanoma, regardless of the country 
of birth [3, 161, 164]. 
Other than the duration of residency, one of the main determinants of risk among 
immigrants’ is their age of arrival to Australia [161]. Australian investigators have described 
a “critical period” for immigration which appear to determine later susceptibility to 
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melanoma [160]. Specifically, arrival before age 10 appears to be associated with the highest 
melanoma risk, similar to that of native-born Australians. In contrast, those arriving after 
age 15 have one-fourth the risk of those arriving prior to age 10 [4, 139, 160, 163]. 
Interestingly, these investigators have also noted a correlation between the total nevus count- 
-which, as explained before, is the single-most significant determinant of melanoma risk— 
and the age of immigration to the sunnier climate, and therefore, sun-exposure [4, 139, 163]. 
Higher nevus counts were recorded among those who had migrated during early childhood. 
Such findings lend more support to the etiologic role of sunlight in the induction of both 
benign nevi and melanoma: early childhood is a crucial age for establishing lifetime 
melanoma risk, and this risk is connected to the induction of nevi [163]—i.e., early exposure 
is more successful at invoking a large pool of “potential precursor” lesions or CAMN [91]. 
Other investigators have focused on childhood, adolescence, and early adulthood as 
periods of potentially intense sun exposures [234], Australian investigators evaluating sun 
exposure by age, have reported an association between increased melanoma risk and high- 
intensity exposure during the age periods of 10 to 24 years and 25 to 39 years [163]. (Solar 
exposure was estimated in terms of mean annual sunshine hours at each residence.) In 
contrast, the total outdoor sun-exposure (recreational or occupational) was not associated 
with melanoma risk in the cases as compared to local controls in this sun-loving Australian 
community. (However, some studies do not corroborate these findings [97, 163]). 
Meanwhile, studies from western Canada have found recreational, and not occupational, sun 
exposure to be associated with increased melanoma risk, even after factoring in skin 
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pigmentary characteristics [98], This further supports the link between intermittent sun 
exposure in young adult life and melanoma. 
Other studies have documented a clear association between increased melanoma risk 
and sunburns and “poor tanning” during adolescence, or “long vacations in sunny climates” 
during childhood [133, 137, 211, 224, 281]. U.S. investigators have correlated a 
significantly increased melanoma risk with a history of 2 or more blistering sunburns 
between the ages of 15 and 20 years, as opposed to beyond 30 years of age [353]. Others, 
following restratification of the data by sex and tanning ability, have implicated mere 
erythema, without pain or blistering, as a possible risk factor [211]. 
Concomitantly, studies from the United States examining the two factors of latitude 
and age simultaneously, have reported the risk to rise inversely with the latitude of one’s 
residence during ages 15 to 20 years, while finding no such association for ages greater than 
30 years [353]. These findings are crucial in pinpointing the etiologic significance of sun 
exposure that occurs decades prior to the peak onset of melanoma, in defining melanoma 
risk, an association which is consistent with melanoma’s long latency period [91]. 
Body Site Distribution: The body site distribution of melanoma differs drastically 
from that of non-melanoma skin cancers (NMSC)—basal cell and squamous cell carcinomas- 
which are related to cumulative, low-grade lifetime sun exposure. This difference implicates 
the significant etiologic role of intense, intermittent sun exposure—as through leisure 
activities—in the development of melanoma [5, 181]. Whereas NMSC have a predilection 
for areas of greatest cumulative, low-grade sun exposure, such as the face, ears, neck, and 
the dorsum of the hands, melanoma predominates on intermittently exposed areas of the 
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body, such as the trunk and the lower limbs [15, 77, 181, 207, 248, 362], with a tendency to 
spare doubly-shielded areas such as the buttocks, genitalia, breasts (in women), and scalp (in 
women) [212]. Furthermore, there are distinct gender-based differences in the anatomic 
distribution of melanoma, with both men and women affected frequently on the back, but 
women affected on the lower extremities, especially the calves (a low-incidence site among 
men) [72]. Studies have revealed a 40-fold variation in the frequency of melanoma per unit 
body surface area at different anatomic locations, the frequency of which correlates with 
patterns of intermittent sun exposure [94], 
Temporal trends in melanoma incidence over a 20-year period further substantiate 
this theory, given that the incidences have changed at different rates for different anatomic 
sites of the body. While the incidence of limb and trunk melanomas rose dramatically during 
this time period, that of head and neck melanomas remained virtually unchanged [93, 95, 
129, 166, 230, 231, 323, 333]. Also, on the extremities, there was relatively little change in 
the incidence of hand melanomas, as compared to melanomas on the remainder of the arm 
[83]. Moreover, over this time period, there were increased rates of lower limb melanomas 
in females and of trunk melanomas in males [93], Factors that may explain these temporal 
trends include changed fashion styles (with exposure of female legs by short skirts, and male 
ears and scalp by shorter haircuts), thinner clothing, and the growing popularity of bathing 
suits and sun-related activities such as sun-bathing. All of these factors may contribute to 
greater sun exposure to previously shielded areas [61, 163, 175, 209, 231, 332]. 
Occupation and Socioeconomic Status: Epidemiologic studies comparing the 
incidence of melanoma among indoor and outdoor workers substantiate the intermittent 
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exposure theory of melanoma. Professionals, office workers, and indoor technical workers 
have higher incidences of melanoma when compared to outdoor workers like farmers and 
construction workers, while the reverse holds true for non-melanoma skin cancers [5, 76, 97, 
99, 342]. Others have reported a direct relationship between melanoma risk and measures 
of socioeconomic status [109]. One study reported the melanoma risk to increase 
significantly with increasing salary among men [266], Still other studies have found no 
association between melanoma and outdoor occupational sun exposure [8], Investigators 
have documented an excess risk of melanoma on the trunk and limbs (normally covered 
areas) but not the head and neck of indoor office workers, as compared to those with outdoor 
occupations [25]. Of note, one study found that the risk of melanoma was actually 
significantly reduced in the presence of a permanent, deep, and even tan [99]. Also, the 
highest melanoma mortality rates have been documented in professional, managerial, and 
clerical workers [64, 208]. 
All of the above evidence further supports the role of intermittent, intense sun- 
exposure in the etiology of melanoma, given that the population of indoor workers has 
greater susceptibility to sunburns as a result of its normally untanned skin. An additional 
factor could relate to their higher incomes, which allows therm greater opportunities for 
outdoor leisure acitivities and tropical vacations [266], For instance, in Sweden, persons of 
higher SES were shown to be more likely than low SES individuals to visit southern Europe 
during vacations [42], Notably, the association between melanoma risk and socioeconomic 
status, as defined by either occupation or income, has held true for men, but not women; this 
was explained by the observation that, most of the women in the reported studies were 
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married, with lower-paying occupations than their husbands, but most probably the same 
recreational activities (and sun exposure) as their husbands [266]. This theory was tested in 
the population of England and Wales, where the women, after being classified according to 
their husbands occupations, were documented to have the same melanoma risk as men in the 
same SES [208]. 
Some investigators have offered an alternate explanation for the observed 
associations between melanoma risk and SES, stating that those with more disposable 
income may have greater awareness of health issues, and consequently, a greater likelihood 
of detecting possible lesions [266], In a survey of persons attending the Melanoma/Skin 
Cancer Screening sponsored by the American Academy of Dermatology, it was found that 
most attendants were well-educated [184], Similarly, an Australian study found a correlation 
between higher education levels and greater probabilities of periodic screenings for 
melanoma [128]. 
Physical, Non-Solar Ultra-Violet Radiation: UVR from a variety of non-solar 
sources has been related to increased risk of melanoma. Artificial sources of light differ in 
their spectral distribution of UVA and UVB, with UVB considered to have the greatest 
mutagenic and carcinogenic potential [219, 256], Sunbeds and sunlamps have been the best- 
publicized artificial lighting source, associated with a relative risk of 2.9, which becomes 
even higher in the case of (primarily UVB-emitting) domestic tanning devices [119, 162, 
260, 331, 348]. Nearly all U.S. tanning salons have UVA-emitting devices. 
Personal History of Non-Melanoma Skin Cancer: Personal history of non-melanoma 
skin cancer, related to cumulative sun damage, has also been shown to be significantly 
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associated with higher melanoma risks [136, 159, 160]. A population-based survey of 1973 
patients with basal cell carcinoma known to the Swedish Cancer Registry, documented 
significantly elevated relative risks of melanoma in both men (RR=6.8) and women 
(RR=4.2) [214]. Also, a review of 3,260 patients revealed a 7-fold increase in melanoma risk 
in those with a prior personal history of basal cell carcinoma. Likewise, actinic keratoses, 
also related to cumulative sun exposure, are related to a 3- to 5-fold increase in melanoma 
risk [133, 138, 160, 232,280]. 
Xeroderma Pigmentosum: Xeroderma pigmentosum is a rare autosomal recessive 
disease, characterized by defective repair of DNA damaged by UVB. Thus, the disease is 
characterized clinically by an excessive sensitivity to the sun, and biologically, by cellular 
hypersensitivity to the mutagenic effects of UVB. Patients have a 2000-fold risk of 
developing melanoma as compared to the general population [58, 197]. 
VI. Other Pigmented Lesions: 
Congenital Melanocytic Nevi: Congenital melanocytic nevi (CMN) are distinguished 
from common acquired melanocytic nevi (CAMN) by their presence at birth. They are 
further subclassified into three categories on the basis of their size: small CMN are less than 
1.5 cm in diameter, while medium and large (or giant) CMN measure 1.5-20.0 cm, and 
greater than 20.0 cm in diameter, respectively [144], The melanoma risk, and therefore, the 
management issues surrounding each CMN category varies substantially [1, 188, 205, 298, 
349], 
Giant congenital melanocytic nevi (GCMN) are considerably more rare, as compared 
to small CMN, occuring in approximately 1 in 20,500 live births by some estimates [52], and 
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1 in 100,000 to 1 in 500,000 (depending on racial factors and size criteria used) by others 
[173, 205, 276, 277, 282, 285, 290, 291, 307, 338, ;KK,14-15]). In terms of their clinical 
appearance, they have a characteristic morphology, comprised of a grossly irregular surface, 
marked by hyperpigmentation with varying shades of brown and hypertrichosis [233]. The 
risk of melanoma in GCMN has been a matter of much controversy [89, 169, 269, 284], 
estimated at 5%-20% over the lifetime—which constitutes a greater than 17-fold increased 
risk of melanoma over the general population [220, 255]. However, a research team at NYU 
is conducting a prospective melanoma surveillance in a group of patients with GCMN, which 
should yield a more precise estimate of melanoma risk in such persons [124], 
In terms of their natural history, about half of all melanomas associated with GCMN 
are diagnosed within the first 3 to 5 years of life, with an additional 10%-20% occuring 
before puberty [220, 277, 307]. Of note, 40% of all childhood melanomas arise from giant 
congenital nevi [170]. Concurrently, melanomas associated with GCMN carry a graver 
prognosis as a result of several intrinsic features. First, they develop deep in the dermis and 
subcutaneous tissue, as well as in the central nervous in the setting of neurocutaneous 
melanosis, which renders them difficult to detect at an early stage. Second, the respective 
melanoma cells are highly anaplastic, with a greater propensity toward early and rapid 
metastases [220, 276, 282, 350]. These considerations have led to the recommendation that 
all such nevi be excised as early as technically feasible; however, with up to 50% of the 
melanomas developing in the CNS or as unknown primaries, this has been questioned [173, 
205,276, 282, 285,291,338], 
. 
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Small- and medium-sized CMN (SCMN) are more prevalent than giant ones, 
appearing in approximately 1% of newborns [52]. SCMN also predispose to melanoma, 
although at lower rates than GCMN. Moreover, the actual estimates for the rate of 
transformation of these lesions into melanoma remains a matter of controversy, because most 
estimates are based on histologic analyses, and there are no definitive histologic criteria for 
distinguishing between acquired melanocytic nevi and small congenital nevi [169]. In a 
histologic survey of 234 melanoma specimens, 64 (27.4%) were contiguous with a dermal 
nevocellular nevus, of which 19 (8.3% of all the melanomas) contained histologic markers 
of congenital nevi [284]. Such studies attribute an estimated cumulative incidence risk of 
2.6%-4.9% to SCMN up to age 60, an 18-fold increase in risk over the general population 
[283]. (Again, such analyses may over-estimate the actual risk, given that there is no 
histologic means of differentiating acquired from congenital nevi [288]). 
In terms of their natural history, unlike GCMN, SCMN rarely progress to melanoma 
before 12 years of age, and consequently, most specialists recommend that they be carefully 
observed until puberty, at which time they may be removed under local (and not general) 
anesthesia, given the greater likelihood of patient cooperation at that point. However, others 
advocate early surgical excision for immediate assurance, as well as freedom from the need 
for life-long follow-up (and its added economic burden) [89, 165, 169, 188, 283, 284, 301]. 
In a survey, 50% of the physicians opted for early excision, while 27% recommend long¬ 
term observation [89]. 
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Interestingly, the presence of “congenital-looking nevi” (large in size but not 
“atypical” in appearance) in the familial melanoma setting was associated with an 8.5-fold 
increased risk, as compared to those with only atypical nevi [195], 
Lentigo Maligna (Melanoma): Lentigo maligna (LM), which represents in situ 
melanoma, is related to cumulative exposure to ultra-violet radiation [209], thus sharing the 
same epidemiologic distribution as basal cell and squamous cell carcinomas—i.e., it 
frequently appears on the face and other chronically sun-exposed skin surfaces of middle- 
aged and elderly individuals [21, 171, 241]. 
Clinically, LM is a large, haphazardly pigmented, irregularly bordered, macular 
lesion, ranging in color from tan to brown to dark brown to black. At times, the lesions may 
show signs of regression, presenting as “lightened” or “normal-looking” areas within the 
pigmented lesion. Over time, these lesions tend to expand slowly, become more haphazardly 
pigmented, and may undergo invasive change, heralded by the appearance of focal indurated 
papules or a diffuse elevation of the entire lesion [144, 290]. If not recognized and treated, 
the invasive form can lead to metastases and death. The interval for this invasive 
transformation has been estimated to be very long, at least 5-15 years, as based on patient 
reports [249], 
Histologically, LM is marked by the hyperplasia of a single layer of melanocytes, 
with a hyperpigmented basal epidermal layer, where the pigment density is independent of 
the amount of sun-exposure—i.e., it does not increase following sun exposure [138]. The 
melanocytes are atypical in appearance, with a disordered proliferation within an atrophic 
epidermis, which overlies a sun-damaged dermis-i.e., solar elastosis [54, 160, 177], 
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Lentigo maligna melanoma (LMM) accounts for only 5% of all cases of melanoma 
[290]. Each individual LM lesion has an unclear risk of progressing to invasive melanoma 
[177, 242, 267, 352]. Estimates of the incidence of invasive transformation vary between 
sources, ranging from 5%-10% to 25%-50%, depending on the study [171, 351, 352]. Thus, 
LM is considered to be associated with a 10-fold increase in melanoma risk up to age 75 
[352]. Even though LM is generally considered to be a slow-growing lesion, there have been 
occasional reports of rapidly-growing cases [171, 245]. When controlled for Breslow depth, 
LMMs have the same prognosis as other forms of melanoma. Surgical excision, usually the 
preferred form of treatment [245], may not be practical or acceptable, given the high 
associated morbidity of facial scars [188]; so, when the lesions are large in size or the patient 
is very old, alternate therapies include radiation therapy and cryosurgery. 
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Materials and Methods1: 
From June to November of 1992, 94 individuals were enrolled in the study after 
receiving an explanation of the protocol, and giving oral consent to participate in it. The 
subjects were recruited from three Yale University dermatology clinics: 69 from the 
Pigmented Lesion Clinic2 (PLC), 18 from a university general dermatology clinic (UGDC), 
and 7 from a hospital general dermatology clinic (HGDC) (Table 2). 
Of the original 94 subjects, 86 finally qualified for the study (66 PLC, 17 UGDC, and 
3 HGDC), while 8 subjects (3 PLC, 1 UGDC, and 4 HGDC) were disqualified, as they failed 
to complete the follow-up questionnaire (Table 2). Of the 86 subjects, 33 had a personal 
history of cutaneous melanoma [M], 22 with and 11 without atypical nevi; 33 had atypical 
nevi only [N]; and 20 served as controls [C] (Table 4). All of the melanoma patients and 31 
(94%) of the atypical nevus patients were recruited from the PLC; and 2 (10%) of the 
controls were enrolled through the PLC: one attended the PLC because offalsely believing 
in having atypical nevi due to a history of non-melanoma skin cancer in his father, while the 
other attended the clinic due to a history of melanoma in her husband. The subjects ranged 
in age from 18 to 85 years (mean=45), with a mean age of 47, 38, and 54 years for the 
melanoma, nevus, and control groups, respectively. The control and melanoma groups were 
significantly older than the nevus group (p=0.001); (Table 3). 
All subjects with a history of melanoma had histologic confirmation of their 
diagnosis. Of the atypical nevus subjects, 25 had histologic confirmation of their diagnosis 
[257], with biopsy specimens demonstrating architectural disorder, with or without cellular 
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atypia, while 8 were diagnosed clinically [142], based on the appearance of their nevi as 
evaluated by a dermatologist (Table 4). 
At the initial evaluation, all subjects received a total body skin examination by the 
dermatologist, which included a complete nevus count, removal of all lesions suspicious for 
early melanoma, and photography of the most atypical pigmented lesions, if any. Following 
the skin examination, all subjects completed a questionnaire which assessed baseline 
knowledge of clinical characteristics and risk factors for cutaneous melanoma, as well as 
general health-seeking attitudes and behavior. The questionnaire was divided into three 
sections, each of which evaluated a different area of knowledge regarding melanoma: (1) 
clinical signs, e.g., irregularities of color or shape, the presence of bleeding, itching, or 
tenderness, and increase in thickness; (2) melanoma facts, e.g., curability with early surgery 
and familial predisposition, and (3) risk factors, e.g., phenotypic characteristics like skin 
type, blue eyes, and red hair, presence of many nevi or atypical nevi, history of sunburns, and 
personal or family history of melanoma. In order to assess each subject’s general health¬ 
seeking practices, the questionnaire also inquired about his/her body awareness, frequency 
of skin self-examination, and the number of health visits in the previous year. Information 
was also obtained regarding each subject’s sun-exposure habits, use of sunscreens, self¬ 
estimate of nevi, and personal and/or family histories of melanoma and non-melanoma skin 
cancers. 
Moreover, each subjects was screened for the presence of various melanoma risk 
factors. These included the total nevus count—both objectively, as ascertained by a 
physician3, and subjectively, as reported by the subject him/herself—a subject’s own 
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impression of “having more nevi than the average individual”, a subject’s personal history 
of atypical nevi and non-melanoma skin cancer, and finally, his/her family history of 
melanoma and non-melanoma skin cancers. 
The questionnaire was followed by a ten-minute educational video that reviewed 
recent epidemiologic trends in melanoma incidence and mortality, melanoma risk factors and 
clinical characteristics, while also emphasizing sun-safe behavior, regular skin self¬ 
examinations, and the use of a “buddy” for examination of difficult-to-see regions of the 
body. The video, prepared through the collaboration of Yale University's Dermatology, 
Epidemiology and Public Health, and Audiovisual departments, combined a factual and 
didactic tone with the emotional story of a family’s loss to melanoma, in order to further 
reinforce its messages. 
The follow-up questionnaires were completed by either mail (n=66), telephone 
(n=ll), or during return clinic visits (n=9); (Table 2). The time period between the 
preliminary questionnaire and the follow-up questionnaire ranged between 4 and 22 months, 
with 94% completed within 14 months. 
Analysis: The analyses were performed using the SAS statistical analysis program, 
with a comparison of knowledge and SSE practices by group and clinic at both baseline and 
follow-up. Both the degree and proportion of improvement were analyzed as a function of 
the various variables—the former through the mean change, and the latter as the proportion 
of subjects to progress from an incorrect response at baseline to a correct one at follow-up. 
'All the work for the study—the recruitement of subjects, completion of post-questionnaires, chart reviews, data 
analysis, and literature review—were performed by the student. The questionnaire assessing the subjects’ 
knowledge-base was adopted from a previous pilot study (performed with an educating nurse as opposed to 
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an educational video), with only minor modifications to the sections on subjects’ skin self-examination 
practices. Dr. Bolognia, M.D. was the dermatologist who examined all the subjects, while Dr. Berwick, Ph.D. 
was the epidemiologist providing advice regarding the analyses. 
2 On their first visit to the Pigmented Lesion Clinic, patients received a folder with information on melanoma 
risk factors (including common acquired melanocytic nevi, atypical nevi, sun exposure, and sunburns), the 
signs and symptoms of melanoma and non-melanoma skin cancers, precautions regarding sun exposure, and 
finally, the importance of early detection through regular skin self-examinations. These pamphlets included 
the following: Why You Should Know About Melanoma; theABCDs of Moles and Melanomas; Dy>splastic Nevi 
and Malignant Melanoma: a Patient’s Guide; What You Need to Know About Moles and Dysplastic Nevi4, 
What You Need to Know About Skin Cancer, Fry Now, Pay Later, For Every Child Under the Sun: A Guide 
to Sensible Sun Protection; Facts About Sunscreens; Sunless Self-Tanners: the Safer Tan; Solumbra Sun 
Protective Clothing and Accessories4, and finally, some general information on melanoma prevention and the 
Pigmented Lesion Clinic at Yale. 
3 One control subject did not receive an objective, physician-determined total body nevus count, being that she 
was recruited from the UGDC of a second dermatologist and refused a total body skin examination by the 




I. Demographic and Phenotypic Characteristics: 
The demographic characteristics of the patient population are shown in table 3. There 
was a predominance of females in all the groups, in approximately a 3:2 to 3:1 ratio, with no 
statistically significant differences between the groups (Table 3). (Of note, the dermatologist 
following the Pigmented Lesion Clinic patients and one of the University General 
Dermatology Clinics from which most of the control subjects were recruited is also female.) 
The mean age for the melanoma and the control groups (47 [A] and 54 [A] years old, 
respectively) was significantly higher than that for the atypical nevus group (38 [B] years 
old). The largest proportion of nevus patients was in the 18 to 35 year-old age-group, (n=15 
(45%)), as compared to the melanoma and control groups, in which the highest proportion 
of subjects were greater than 51 years old (n=14 (42%) and 13 (65%), respectively) 
(p=0.001); (Table 3). 
Data on the highest educational level attained by each subject was not available, so 
the occupational scores were used as a proxy for the socioeconomic status. There were no 
statistically significant differences in socioeconomic status among the groups (Table 3). 
Data regarding phenotypic characteristics such as hair and eye color, and skin 
susceptibility to bums and ability to tan, were based on participants’ subjective self-reports. 
There were no statistically significant differences between the groups with respect to these 
phenotypic characteristics (Table 3). 
* 
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In the melanoma group, approximately one-third of subjects had blond/red, light 
brown, and brown/black hair, each. In contrast, in the nevus and control groups, the highest 
proportions of subjects had brown/black hair (n=21 (64%) and 11 (55%), respectively). 
These differences were not significant (Table 3). 
Most melanoma subjects (n=21 (64%)) had blue/green eyes, as compared to the 
nevus and control subjects, who mostly had blue/green or light/dark brown eyes (n=l 5 (45%) 
and 13 (39%) for the nevus group and 8 (40%), each, for the controls). These differences 
were not statistically significant (Table 3). 
To define the skin types, two characteristics were emphasized: (1) the predisposition 
to sunburns in reaction to acute sun-exposure and (2) the ability to tan in response to chronic 
sun-exposure. These two characteristics, related to inherent skin pigmentation, influence 
individuals’ risk of melanoma, as described in the introduction. Interestingly, in all three 
groups, the majority of subjects reported experiencing painful sunburns, or mild sunburns 
followed by a slight tan (n=30 (90%), 30 (91%) and 14 (70%) for the melanoma, nevus and 
control groups, respectively). Also, none of the melanoma subjects, as compared to 1 (3%) 
nevus and 2 (10%) control subject(s), reported tanning without a sunburn in response to 
acute sun-exposure. These differences were not significant (Table 3). 
The majority of subjects in all three groups reported a history of either mild tans with 
several peelings, or of moderate tans, in response to chronic sun-exposure (n=21 (64%), 19 
(58%), and 9 (45%), for melanoma, nevus, and control groups, respectively). Also, only 2 
(6%) melanoma subjects, as compared to 5 (15%) nevus and 4 (21%) controls reported 
developing a deep tan (Table 3). 
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II. Risk Factors: 
The objective, physician-determined total body nevus count was significantly 
different between the groups (p=0.001). The majority of the melanoma subjects had less 
than 33 nevi (n=20 (61%)), and only 3 (9%) subjects had greater than 67 nevi. In the nevus 
group, most subjects had either 0-33 or 34-66 nevi (n=12 (36%) each), while 9 (27%) 
subjects had greater than 67 nevi. In contrast, all control subjects had 0-33 nevi (Table 4). 
There were statistically significant differences in the groups’ subjective, self-reported 
total body nevus counts (p=0.001). The majority of melanoma subjects (n=19 (58%)) 
reported total body nevus counts of 0-33, while the majority of nevus subjects believed they 
had greater than 67 nevi (n=16 (48%)). Most controls estimated their total body nevus 
counts to be less than 33 (n=17 (85%)). These self-assessed total nevus counts were correct 
in 17 (52%) melanoma, 18 (55%) nevus, and 17 (85%) control subjects. These results had 
borderline statistical significance (p=0.051); (Table 4). 
Each participant’s subjective impression of having “more-than-average numbers of 
nevi” was also assessed. The fact that 12 (36%) melanoma, 23 (70%) nevus, and 4 (20%) 
control subjects reported having greater-than-average nevus counts was not significant 
(Table 3). Given that the average individual has a total nevus count of approximately 20-30, 
the proportion of subjects who correctly believed in having (or not having) more-than- 
average numbers of nevi was calculated. The objective, physician-determined nevus count 
was used as the gold standard. Twenty-four (73%) melanoma, 27 (82%) nevus, and 14 
(70%) control subjects correctly estimated their nevus counts to be either average or greater- 
than-average, with no significant differences between the groups (Table 4). 
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There were significant differences in the group incidences of atypical nevi (AN), with 
either a clinical or a histologic diagnosis in 22 (67%) melanoma, 33 (100%) nevus, and 1 
(5%) control subject(s) (p=0.001); (Table 4). 
The three groups reported similar incidences of a personal history of non-melanoma 
skin cancer, with positive self-reported histories in 5 (15%) melanoma, 5 (15%) nevus, and 
4 (20%) control subjects (Table 4). 
Nine (27%) melanoma, 14 (42%) nevus, and 3 (15%) control subjects reported a 
family history of malignant melanoma. Of these subjects, 6 (67%) melanoma, 10 (71%) 
nevus, and 0 control subjects had histologic documentation of that family history in the 
medical records (Table 4). 
Sixteen (48%) melanoma, 11 (33%) nevus, and 4 (20%) control subjects related a 
family history of non-melanoma skin cancer; however, histologic documentation of these 
self-reported cases were not sought (Table 4). 
III. Knowledge Scores on Individual Questions: 
The baseline and follow-up questionnaires contained the same series of questions so 
as to enable the evaluation of subjects’ baseline melanoma knowledge, as well as the 
improvement in that knowledge as a result of the intervention. The knowledge scores were 
analyzed by both group and clinic—i.e., for part of the analysis, the melanoma and nevus 
groups were combined into a single “Pigmented Lesion Clinic” or “PLC” group, which was 
then compared to the controls. Of note, our analyses (as shown in Tables 5 & 6) revealed 
that in many instances, the melanoma and nevus groups performed similarly on the 
questions—with at times even superior performance on individual questions among nevus 
■» 
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subjects. In these instances, an increased significance (lower p-value) emerged when the 
PLC group was compared to the controls, as opposed to when all the groups were compared 
to one another. Thus, when the melanoma and nevus groups had similar knowledge levels, 
the “PLC vs. control” data were reported; this also simplified the discussions. However, the 
tables for both methods of analysis are included. 
Clinical Characteristics of Melanoma were emphasized in the video, because to be 
an effective (skin) self-examiner, each individual needs a working knowledge of melanoma 
signs and symptoms, so as to be able to identify a suspicious lesion and bring it to his/her 
dermatologist’s attention. In the questionnaires, the subjects’ awareness of the signs and 
symptoms of melanoma were explored through nine questions, which are discussed below. 
• 66 (100%) PLCs and 18 (90%) controls correctly identified a change in nevus shape, 
color, or size as a potential marker for melanoma at baseline (p=0.01). The proportion with 
the correct answer—i.e., 63 (95%) and 19 (95%), respectively—was the same post¬ 
intervention (Table 6). 
• 65 (98%) PLCs and 13 (65%) controls correctly identified abnormal shape as a 
potential sign of melanoma at baseline (p=0.001). This proportion was 64 (97%) and 16 
(80%), respectively, at follow-up (p=0.009). There was a significantly higher proportion of 
controls (n=5 (25%)) who learned this fact post-intervention, as compared to the PLCs (n=l 
(2%)); (p=0.001); (Table 6). 
• 62 (94%) PLCs, as compared to 13 (65%) controls, correctly identified dark and 
variegated color as a potential marker for melanoma at baseline (p=0.001). This proportion 
was 64 (97%) and 17 (85%), respectively, at follow-up (p=0.046). The proportion of 
- 
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controls (n=5 (25%)) who had learned this fact was significantly higher than that of the PLCs 
(n=4 (6%)); (p=0.016); (Table 6). 
• Twenty-seven (82%) melanoma, 31 (94%) nevus, and 14 (70%) control subjects 
correctly identified an increasing nevus thickness as a potential sign of melanoma at baseline 
(p=0.021); the post-intervention proportion, at 27 (82%), 27 (82%), and 17 (85%), 
respectively, was not statistically significant. However, that 5 (25%) controls, as compared 
to 5 (15%) melanoma and 1 (3%) nevus subject(s) had learned this fact post-intervention, 
was significant (p=0.018); (Table 5). 
• There were no significant differences at either baseline or follow-up in the proportion 
of subjects correctly identifying a non-healing scab/lesion as a potential melanoma: 54 
(82%) PLCs and 17 (85%) controls at baseline, as compared to 54 (82%) PLCs and 19 (95%) 
controls at follow-up (Table 6). 
• The analysis, by group, of bleeding as a sign of melanoma yielded significant 
differences at both baseline and follow-up. Twenty-four (73%) melanoma, 29 (88%) nevus, 
and 9 (45%) control subjects correctly identified bleeding as a potential marker for 
melanoma at baseline (p=0.001). The post-intervention proportion was 23 (70%), 31 (94%), 
and 14 (70%), respectively (p=0.021). The controls displayed not only a significantly higher 
mean change in knowledge [A], but also a significantly higher proportion of intervention- 
related incorrect-to-correct answers—n=6 (30%) controls as compared to no melanoma and 
2 (6%) nevus subjects; (p=0.013); (Table 5). 
• 46 (70%) PLCs and 9 (45%) controls correctly identified tenderness in a nevus as a 
potential sign of melanoma at baseline (p=0.045). This proportion-43 (64%) and 15 (75%), 
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respectively—was similar post-intervention. Here, the mean learning was significantly higher 
among the controls [A]. Also, a significantly higher proportion of controls (n=7 (35%)), as 
compared to PLCs (n=5 (8%)), changed from an incorrect to a correct answer post¬ 
intervention (p=0.002); (Table 6). 
• The analysis, by group, of itching as a potential sign of melanoma yielded significant 
differences at both baseline and follow-up. Eighteen (55%) melanoma, 25 (76%) nevus, and 
4 (20%) control subjects were knowledgeable of this fact at baseline (p=0.001). This 
proportion had increased to 19 (58%), 27 (82%), and 7 (35%), respectively, at follow-up 
(p=0.001). That 7 (35%) controls learned this fact, as compared to 8 (12%) PLCs, was 
statistically significant (p=0.019); (Table 6). 
• The analysis, by group, of nevus “size” as a marker of melanoma also pinpointed 
significant differences between the groups at both baseline and follow-up. Twenty-three 
(70%) nevus, as compared to 13 (39%) melanoma and 3 (15%) controls correctly identified 
large size as a potential sign of melanoma at baseline (p=0.001). This proportion—15 (45%), 
22 (67%), and 8 (40%), respectively—was of borderline significance post-intervention 
(p=0.045). The mean increase in knowledge was significantly higher among the controls 
[A], while the proportion of changes from an incorrect to a correct answer was also higher 
among the controls (n=5 (25%)), as compared to the melanoma (n=5 (15%)) and nevus (n=l 
(3%)) groups (Table 5). 
In this section, the PLC population most frequently missed questions about itchiness, 
tenderness, and size in melanoma. Meanwhile, the controls were most suspicious of non¬ 
healing lesions, or lesions changing in thickness, color, shape, or size, and least suspicious 
t 
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of factors such as bleeding, tenderness, itching, size, abnormality in shape, and darkness and 
variegation in color. Also, the controls, with the worst baseline performances, displayed the 
most significant improvements in knowledge. 
The Survey of Back Nevi was one of the points emphasized in the video. Given that 
a significant proportion of melanomas originate on the upper back—the most common site 
in males, and the second-most common site in females—it was important to raise participants' 
awareness of this difficult-to-self-examine area of the body, and educate them about 
alternative examination methods, such as using a mirror or a "buddy". In this respect, 33 
(50%) PLCs as compared to 6 (30%) controls were aware of these examination methods at 
baseline. This proportion increased to 44 (67%) PLCs and 16 (80%) controls at follow-up, 
with the improvement in the control group [A] being statistically significantly higher than 
that of the PLCs [B], Moreover, a significantly higher proportion of controls improved 
(n=l 1 (55%)) as compared to the PLCs (n=19 (29%)); (p=0.032); (Table 6). 
Factual Knowledge of melanoma characteristics, risk factors, and treatment/cure was tested 
through six true-false questions, as discussed below. 
• 64 (97%) PLCs as compared to 18 (90%) controls correctly identified a history of 
severe childhood sunburns as a significant risk factor for melanoma. This proportion—65 
(98%) PLCs and 19 (95%) controls-was almost unchanged at follow-up (Table 6). 
• At baseline, 62 (94%) PLCs as compared to 18 (90%) controls recognized that the 
only cure for melanoma is early surgical excision—not statistically significant. This 
proportion—64 (97%) and 17 (85%), respectively—had borderline significance at follow-up 
(p=0.046). However, the change from baseline to follow-up was not significant (Table 6). 
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• 57 (86%) PLCs as compared to 16 (80%) controls correctly identified a positive 
family history of melanoma as a significant risk factor for melanoma at baseline. At follow¬ 
up, this proportion had increased to 62 (94%) PLCs and 17 (85%) controls, respectively. 
However, the change was not statistically significant (Table 6). 
• Almost identical proportions of PLCs and controls (n=51 (77%) and 15 (75%), 
respectively) recognized the statement “An itchy mole could not be melanoma” as false. 
There was almost no change in the proportions at follow-up—52 (79%) PLCs and 14 (70%) 
controls (Table 6). 
• 58 (88%) PLC as compared to 10 (50%) controls recognized that a black and hairy 
mole could not be melanoma at baseline (p=0.001). This proportion was almost unchanged 
at follow-up—58 (88%) PLCs and 12 (60%) controls (p=0.005). However, that 5 (25%) 
controls, as opposed to only 3 (5%) PLCs learned this fact was statistically significant 
(p=0.006); (Table 6). 
• Few subjects recognized that a disappearing mole could potentially represent 
melanoma, with very little improvement at follow-up—5 (15%) melanoma, 14 (42%) nevus, 
and 1 (5%) control subject(s) at baseline (p=0.001), and 9 (27%) melanoma, 16 (48%) nevus, 
and 3 (15%) controls at follow-up (p=0.009); (Table 5). 
In this section, the most frequently missed question in all groups related to a 
disappearing nevus, as a possible natural history for a melanoma. Among controls, there was 
a high awareness of risk factors such as childhood sunburns and a positive family history, 
as well as of cure through early excision. These high levels of baseline knowledge among 
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controls probably reflects knowledge already disseminated through various public media, 
especially in view of the lack of significant change at follow-up. 
Melanoma Risk Factors were also emphasized in the video. To raise an individual’s 
awareness of melanoma risk factors is an empowering act, allowing that individual to assess 
his/her own relative risk of melanoma, which could in turn influence his/her implementation 
of skin self-examination recommendations and sun-safe practices. Thus, the groups’ 
knowledge about melanoma risk factors was explored in the third section of the 
questionnaire, through ten clinical scenarios which were categorized as high- or low-risk. 
• All groups well-recognized a changing nevus as a high-risk lesion—65 (98%) PLCs 
and 20 (100%) controls at both baseline and follow-up (Table 6). 
• Both clinic populations were highly aware of such phenotypic characteristics as blue 
eyes and red hair as significant melanoma risk factors—65 (98%) PLCs and 19 (95%) 
controls at baseline, and 65 (98%) PLCs and 20 (100%) controls at follow-up (Table 6). 
• Both clinic populations were highly aware of a positive family history as a risk 
factor—65 (98%) PLCs and 19 (95%) of controls at baseline, and 64 (97%) PLCs and 19 
(95%) controls at follow-up (Table 6). 
• Both clinic populations were highly aware of the predisposition to melanoma in an 
individual who bums, never tans-65 (98%) PLCs and 18 (90%) controls at baseline, as 
compared to all the subjects (100%) at follow-up (Table 6). 
• Both clinic populations were highly aware of high melanoma risks in individuals with 
many nevi and both family and personal histories of melanoma—64 (97%) PLCs and 19 
(95%) controls at baseline, as compared to all the subjects (100%) at follow-up (Table 6). 
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• Both clinic populations were highly aware of the greater susceptibility to melanoma 
in the presence of a positive personal history-64 (97%) PLCs and 19 (95%) controls at 
baseline, and 64 (97%) PLCs and 20 (100%) controls at follow-up (Table 6). 
• At baseline, there was a statistically significant difference in the groups' awareness 
of the low melanoma risk in individuals with no nevi and dark hair—64 (97%) PLCs and 15 
(75%) controls (p=0.002). However, all subjects (100%) answered the question correctly 
post-intervention. The controls had not only significantly higher mean changes in 
knowledge [A], but also significantly higher proportions of incorrect-to-correct answers post¬ 
intervention—5 (25%)) controls as compared to 2 (3%) PLCs (p=0.002); (Table 6). 
• Both clinic populations were highly aware of the association between large and 
oddly-shaped nevi and melanoma—63 (95%) PLCs and 17 (85%) controls at baseline, and 
64 (97%) PLCs and 18 (90%) controls at follow-up. The controls had higher proportions of 
incorrect-to-correct answers compared to the PLCs (3 (15%) versus 2 (3%), respectively); 
(p=0.046); (Table 6). 
• Both clinic populations were highly aware of higher-than-average (> 50) nevus 
counts as melanoma risk factors-61 (92%) PLCs and 19 (95%) controls at baseline, and 62 
(94%) PLCs and 18 (90%) controls at follow-up (Table 6). 
• All groups appeared to be equally aware of the low-risk status of black skin—54 
(82%) PLCs and 16 (80%)controls at baseline, and 55 (83%) PLCs and 16 (80%) controls 
at follow-up (Table 6). 
In this section, which focused on melanoma risk factors, the performance of the three 
groups was nearly identical, with no significant change in most questions from baseline to 
I 
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follow-up, even among the controls. This might perhaps reflect the recent media focus on 
melanoma as a serious public health hazard, with concomitant campaigns aimed at increasing 
the general awareness of those risk factors. 
IV. Knowledge Scores as Stratified into Percentiles: 
The knowledge scores were stratified into percentiles—defined as 0%, 1 %-37%, 38%- 
74%, and 75%-100%—for each section of the questionnaire, as well as for the total 
questionnaire. Then, the analysis entailed determining the proportion of subjects in each 
group who responded correctly to greater than 75% of the tested material. The scores 
themselves were labeled as score 1 (corresponding to the first part of the /^-questionnaire), 
score la (corresponding to the first part of the /^/-questionnaire), etc., up to score4a 
(corresponding to the post-questionnaire in its entirety). [Again, the sections of the 
questionnaire examined the awareness of melanoma signs and symptoms, melanoma facts 
(in a true-false format), and melanoma risk factors, respectively.] With respect to almost all 
scores, there were significant differences in the proportions in each group attaining a greater- 
than-75% sum. Again, when the performances of the melanoma and nevus groups were 
similar, they were combined into a single PLC group in order to simplify the discussions. 
• In the first section of the questionnaire—on the clinical characteristics of melanoma- 
37 (56%) PLCs, but only 1 (5%) control attained baseline sums greater than 75% (p=0.001). 
Of note, most controls (n=16 (80%)) correctly identified only 38%-74% of the 
characteristics. This difference (by clinic) was no longer significant at follow-up, with 34 
(52%) PLCs and 5 (25%) controls attaining a sum greater than 75%. (In the analysis of the 
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percentiles by group, there was reduced significance, marked by a change in the p-value from 
0.001 to 0.036); (Table 7). 
• In the second section of the questionnaire—testing knowledge of various melanoma 
facts—29 (44%) PLCs, as compared to only 4 (20%) controls, attained baseline sums greater 
than 75% (p=0.027). Again, most controls (n=12 (60%)) were knowledgeable about only 
38%-74% of those facts. At follow-up, these proportions had increased in both populations, 
with 39 (59%) PLCs and 6 (30%) controls attaining sums greater than 75% of the total 
(p=0.005). However, most controls (n=l 1 (55%)) still scored in the 38%-74% range (Table 
7). 
• The third section of the questionnaire—examining knowledge of melanoma risk 
factors—revealed no significant differences between the groups, except for a difference of 
borderline significance between the PLC and control baseline sums. Thus, at baseline, 60 
(91%) PLCs as compared to 14 (70%) controls attained sums greater than 75% (p=0.052); 
this proportion was 61 (92%) and 18 (90%), respectively, post-intervention. In both 
populations, most subjects were highly aware of potential melanoma risk factors (Table 7). 
• The baseline and follow-up total sums were significantly different between the three 
groups. The nevus group had the highest proportions of greater-than-75% sums (at both 
baseline and follow-up). Meanwhile, despite having the lowest proportions of greater-than- 
75% sums at baseline, the control group resembled the melanoma group in its post¬ 
intervention performance: at baseline, 21 (64%) melanoma and 27 (82%) nevus, but only 
6 (30%) controls attained a sum greater than 75% (p=0.001); the post-intervention 
proportions were 20 (61%) melanoma, 29 (88%) nevus, and 13 (65%) controls (p=0.04). Of 
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note, most controls knew 38%-74% of the material at baseline (n=13 (65%)), but greater than 
75% of the material at follow-up (n=13 (65%)); (Table 7). 
V. Baseline, Follow-up, and Improvement in Knowledge Scores by Group, 
Demographic & Phenotypic Characteristics, and Melanoma Risk Factors: 
The means for the baseline and follow-up knowledge scores, along with the mean 
changes, were analyzed with respect to the defined demographic, phenotypic, and high risk 
variables, so as to determine which ones relate to significant increase in knowledge. This 
is especially important in educational interventions, where the main objective is to change 
knowledge, and therefore, behavior. Therefore, a deeper understanding of the factors 
affecting motivation could benefit the intervention’s design, tailoring the strategies used to 
each sub-population’s needs or psychobiological framework. 
For the analysis, the knowledge variables were modeled after the questionnaire 
format, with score 1 denoting the section on the clinical characteristics of melanoma, score2 
delineating the section on melanoma facts, score3 designating the section on melanoma risk 
factors, and score4 representing the total sum. The analysis involved a comparison of the 
means by both group and clinic, and then, within each group, by the various variables. The 
same approach was used to determine the proportion of subjects in each group whose scores 
increased. 
• The analysis of knowledge scores by group revealed the melanoma and nevus groups 
to be highly knowledgeable about melanoma, with usually significantly higher scores as 
compared to the controls. However, the controls had significantly higher improvements in 
knowledge. At baseline, the melanoma and nevus groups’ score 1 means were 6.9 [A] and 
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7.8 [A], respectively, as compared to 5.0 [B] for the controls. (The classification into groups 
A vs. B vs. C indicates the presence of statistically significant differences). At follow-up, 
given the significant increase in knowledge among the controls, the performance of the 
melanoma group resembled that of the controls—with score 1 means of 6.8 [B] and 6.6 [B] 
for the melanomas and the controls, respectively, as compared 7.8 [A] for the nevus group. 
The mean change in scorel was significantly higher among the controls, at 1.6 [A], as 
compared to the almost unchanged scores of the melanoma and nevus groups, at -0.1 [B] and 
0 [B], respectively. Moreover, 13 (65%) controls had increased score Is, as compared to 11 
(33%) melanoma and 6 (18%) nevus subjects (p=0.001); (Table 8a). 
Again, with respect to score2, (melanoma facts), the melanoma and nevus groups had 
significantly higher means at both baseline and follow-up: 5.1 [A], 5.3 [A], and 4.2 [B] at 
baseline, and 5.6 [A], 5.6 [A], and 4.9 [B] at follow-up, for the melanoma, nevus, and control 
groups, respectively. There were no significant differences among the groups in either the 
mean change, or the proportion of subjects with increased score2s, even though both were 
higher among controls; (Table 8a). 
With respect to score3 (risk factors), there were no significant differences among the 
groups in the either baseline or follow-up means, the degree of change, or the proportion of 
subjects with increased scores. However, the melanoma and nevus groups tended to have 
higher means, while the controls had the highest mean change as well the greatest proportion 
of subjects with increased scores; (Table 8a). 
The scored means were again significantly higher in the melanoma and nevus groups, 
as compared to the controls, at 21.6 [A], 22.6 [A] as compared to 18.3 [B] at baseline, and 
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22.0 [B], 23.1 [A], as compared to 21.1 [C] at follow-up, for the melanoma, nevus, and 
controls, respectively. The controls had the significantly higher mean improvements, at 2.8 
[A], as compared to 0.4 [B] and 0.5 [B] for the melanoma and nevus groups, respectively. 
Even though a greater proportion of controls had increased scores, this was not significant; 
(Table 8a). 
• The analysis of knowledge as a function of sex within each group—comprised of the 
melanoma, nevus, control, PLC, and all (the study subjects) groups—revealed generally 
higher knowledge scores among females, as compared to males. However, these differences 
were not statistically significant. Likewise, the tendencies toward higher proportions of 
females improving their scores, as well as greater degrees of improvement among females, 
were not statistically significant. The only exceptions involved follow-up score2s for all 
subjects (5.6 [A] for females and 5.1 [B] for males), follow-up score4s for PLC subjects 
(23.0 [A] for females and 21.5 [B] for males), and the follow-up score4s for all subjects 
(22.6 [A] for females and 21.2 [B] for males); (Table 8b). 
• The analysis of knowledge as a function of age revealed different patterns for 
different groups. In the melanoma group, there was generally greater knowledge with 
increasing age, but greater improvements in the youngest age group. However, none of the 
differences were statistically significant. Nor were there significant differences between the 
age groups in the proportion of melanoma patients with increased scores (Table 8c). 
In the nevus group, by comparison, the younger age groups had significantly higher 
knowledge means as compared to the oldest one. The score 1 means were 8.2 [A], 7.8 [A], 
and 6.2 [B] at both baseline and follow-up, for the 18-35, 36-50, and 51-85 age groups, 
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respectively. The score2s were 5.8 [A], 5.2 [B], and 4.2 [C] at baseline, and 5.8 [A], 5.8 [A], 
and 4.4 [B] at follow-up, for the 18-35, 36-50, and 51-85 age groups, respectively. The 
score3s were 9.8 [A], 9.7 [A], and 8.4 [B] at baseline, and 9.9 [A], 9.8 [A], and 9.0 [B] at 
follow-up for the 18-35, 36-50, and 51-85 age categories, respectively. Finally, the score4s 
were 23.8 [A], 22.7 [A], and 18.8 [B] at baseline, and 23.9 [A], 23.5 [A], and 19.6 [B] at 
follow-up for the 18-35, 36-50, and 51-85 age categories, respectively. Concurrently, the 
older age groups tended to have greater improvements as well as higher proportions of 
individuals with increased scores, although none of these differences were significant (Table 
8c). 
The controls displayed yet another pattern, with the highest means in the youngest 
and/or the oldest age groups. The scorels were 6.7 [A], 3.5 [C], and 5.1 [B] at baseline, and 
7.0 [A], 4.8 [B], and 7.1 [A] at follow-up, for the 18-35, 36-50, and 51-85 age groups, 
respectively. The score2s followed the same pattern, but were not significant. For score3, 
only the follow-up means were significant, at 9.0 [B], 8.8 [C], and 9.9 [A], for the three 
respective age groups. Finally, the score4 means were 19.7 [A], 14.3 [C], and 19.2 [B] at 
baseline, and 21.0 [B], 18.3 [C], and 21.9 [A] at follow-up, for the three respective age 
groups. Again, even though the middle age group had both greater proportions of individuals 
with increased scores, and higher mean improvements, none of the differences were 
statistically significant (Table 8c). 
In the PLC group, the highest means were observed in the youngest age group, with 
statistically significant differences in the follow-up score2s only, at 5.6 [B], 5.8 [A], and 5.3 
[C] for the 18-35, 36-50, and 51-85 age groups, respectively. Even the two older age groups 
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had higher degrees of improvements, as well higher proportions of individuals with increased 
scores, none of the differences were significant (Table 8c). 
When all the subjects were combined, the highest mean scores were seen in the 
youngest age group, however with only a few significant differences: baseline score Is, at 
7.5 [A], 6.8 [B], and 6.3 [C], and baseline score4s, at 22.4 [A], 21.0 [B], 20.4 [C] for the 
respective age categories. Like the PLCs, even though the two older age groups had greater 
degrees of improvement and higher proportions of individuals with increased scores, none 
of the differences were significant (Table 8c). 
• The analysis of knowledge as a function of the phenotypic marker hair color revealed 
different patterns within each group. The overall trend within both the melanoma and nevus 
groups—and by extension, the PLC group-was for higher baseline and follow-up means (for 
all the scores) for subjects with light brown and/or brown/black hair. This was significant 
only with respect to the melanoma baseline score2s, where subjects with blond/red and light 
brown hair had significantly higher means—at 5.3 [A] and 5.5 [A], respectively—as compared 
to those with brown/black hair—at 4.4 [B]. The mean change was not higher for any 
predominant hair color. Also, those with blond/red and light brown hair had the greatest 
proportions of individuals with increased scores. In the melanoma group, 7 (58%) blond/red 
haired, as compared to 3 (27%) and 1 (10%) light brown and brown/black haired individuals, 
respectively, had improved score Is (p=0.017); only 3 (25%) blond/red haired, as compared 
to 5 (45%) and 7 (70%) light brown and brown/black haired individuals, respectively, had 
increased score2s (p=0.038); and 9 (75%) blond/red haired, as compared to 6 (55%) and 3 
(30%) light brown and brown/black haired subjects, respectively, had improved score4s 
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(p=0.038). In the PLC population, 9 (45%) blond/red haired, as compared to 4 (27%), and 
4 (13%) light brown and brown/black haired subjects, respectively, had increased score Is 
(p=0.011); and 14 (70%) blond/red haired, as compared to 8 (53%), and 12 (39%) light 
brown and brown/black haired subjects, respectively, had increased score4s (p=0.03); (Table 
8d). 
Among controls and all the subjects, the follow-up means were consistently highest 
in those with blond/red hair, sometimes with statistical significance. Among controls, the 
follow-up score Is were 8.5 [A] as compared to 6.2 [B] and 6.1 [B], and the follow-up 
score4s were 24.3 [A], as compared to 20.4 [B] and 20.2 [B], for subjects with blond/red, 
light brown, and brown/black hair, respectively. Those with blond/red hair also had the 
highest proportion of subjects with improved scores—except in relation to score3, where their 
perfect mean score of 10 (out of 10) at both baseline and follow-up precluded further 
improvement. These difference were significant in regards to score 1, only, where 4(100%) 
blond/red haired, as compared to 4 (80%) and 5 (45%) light brown and brown/black haired 
subjects, respectively, had increased scores. This trend also applied when all the subjects 
were combined together. In the all group, 13 (54%) blond/red haired, as compared to 8 
(40%), and 9 (21%) light brown and brown/black haired subjects, respectively, had increased 
scorels (p=0.007); and 13 (75%) blond/red haired, as compared to 12 (60%), and 18 (43%) 
light brown and brown/black haired subjects, respectively, had increased score4s (p=0.011); 
(Table 8d). 
• The analysis of knowledge as a function of the phenotypic variable eye color yielded 
less significant results as compared to the variable hair color. Within the melanoma and 
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nevus—and by extension, the PLC—groups, there was a tendency toward higher means 
among, first, light/dark brown eyed, and then, hazel/grey eyed individuals. These differences 
were significant only in the nevus group's baseline score2s, where light/dark brown eyed 
subjects had the highest mean, at 5.6 [A], as compared to 5.3 [B] and 4.4 [C] for those with 
blue/green and hazel/grey eyes, respectively. The mean improvement in knowledge, and the 
proportion of individuals with increased scores, also tended to be highest in those with 
light/dark brown or hazel/grey eyes. In the PLC group, the mean change was greatest among 
hazel/grey eyed subjects, at 1.0 [A], as compared to 0.2 [C] and 0.3 [B] for blue/green and 
light/dark brown eyed ones, respectively (Table 8e). 
Among controls, there were higher means and degrees of change in association with 
either blue/green or hazel/grey eyes. These were significant in the control follow-up score2s, 
where blue/green eyed and hazel/grey eyed subjects had means of 5.6 [A] and 5.3 [A], 
respectively, as compared to 4.3 [C] for those with light/dark brown eyes. Also, among 
controls, the mean score2 increase was highest among blue/green eyed subjects, at 1.5 [A], 
as compared to 0 [B] and 0.5 [B] for hazel/grey and light/dark brown eyed subjects. Controls 
with blue/green eyes also tended to have the greatest proportion of increased scores, although 
these were not significant (Table 8e). 
Among all the subjects, the follow-up means, the mean increases, and the proportion 
of subjects with increased scores tended to be highest in hazel/grey and light/dark brown 
eyed individuals, however without any statistical significance (Table 8e) 
• The analysis of knowledge with respect to the self-reported skin reaction to acute sun- 
exposure revealed almost no significant differences within groups. Melanoma, control, and 
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PLC subjects with a tendency to bum had, in general, higher baseline and follow-up means, 
as well as greater proportions of subjects with increased scores. None of these differences 
were significant, however, other than the follow-up score2s in the control group, where those 
who burned had significantly higher means, at 5.6 [A], as compared to those who tanned, at 
4.6 [B], In contrast, among nevus and all subjects, those who tanned had a tendency toward 
higher means and greater proportions of knowledge increase (Table 81). 
• The analysis of knowledge as a function of the self-reported skin reaction to chronic 
sun-exposure revealed more consistent, though still mostly insignificant, trends. In all the 
subject groupings and with respect to all scores (1-4), those who reported to freckle or 
develop a mild tan after several peelings tended have higher means, as compared to those 
who reported a moderate to deep tan. Among controls, the baseline score4s were 
significantly higher among frecklers, at 20.4 [A], as compared to the tanners, at 18.1 [B], 
Also, in the all group, the baseline score3s and score4s were significantly higher among the 
frecklers—at 9.9 [A] and 22.3 [A], respectively—as compared to the tanners—at 9.3 [B] and 
21.0 [B], respectively. In contrast, the tanners tended to have higher proportions of subjects 
with increased scores throughout, other than in score 1. This might be related to the higher 
baseline and follow-up scores in the frecklers, which left greater room for improvement 
among the tanners. However, none of these were significant. Also, the mean change in the 
scores was usually higher among tanners, except again for score 1, where the frecklers had 
greater mean improvements in knowledge. However, none of these differences were 
significant, other than the mean change in score3 in the all group—0 [B] for frecklers and 0.2 
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[A] for tanners. In this case, the frecklers had nearly perfect baseline and follow-up scores, 
which might contribute to their minimal improvement (Table 8g). 
• The analysis of knowledge as a function of the objective, physician-determined nevus 
count revealed very consistent patterns within all the groups. Although not always 
significant, the highest means were usually observed among those with higher nevus counts 
(34-66 and greater than 67). The degree of improvement did not follow a specific pattern, 
being at times higher among those with 0-33 nevi, and at other times, higher among those 
with greater than 34 nevi. In contrast, in most cases—except for score4—those with 0-33 nevi 
had the highest proportion of subjects with increased scores (Table 8h). 
None of these differences were significant in the melanoma group. In the nevus 
group, there were significant differences in the follow-up score Is and score4s, at 8.4 [A] and 
8.4 [A], as compared to 6.6 [B] (for the scorels), and 23.8 [A] and 23.9 [A] as compared to 
21.7 [B] (for the score4s), for those with 34-66, greater than 67, and 0-33 nevi, respectively. 
In the nevus group, the mean changes in score 1 and score2 were also significant at 0.9 [A] 
and -0.1 [B] as compared to -0.8 [C] (for the scorels), and -0.2 [C] and 0.1 [B] as compared 
to 0.9 [A] (for the score2s) in those with 34-66, greater than 67, and 0-33 nevi, respectively 
(Table 8h). 
In the PLC group, both the baseline and the follow-up scorels and score4s were 
significantly higher among those with greater than 34 nevi. The actual means were 7.4 [B] 
and 8.3 [A] as compared to 6.9 [C] (for the baseline scorels), 7.9 [A] and 8.2 [A] as 
compared to 6.5 [B] (for the follow-up scorels), 22.7 [B] and 23.3 [A] as compared to 21.2 
[C] (for the baseline score4s), and finally, 23.5 [A] and 23.5 [A] as compared to 21.5 [B] (for 
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the follow-up score4s), for those with 34-66, greater than 67, and 0-33 nevi, respectively. 
Also, in the PLC group, the mean score 1 increase was significantly higher among those with 
greater nevus counts—0.5 [A] and -0.2 [B] as compared to -0.4 [C], for those with 34-66, 
greater than 67, and 0-33 nevi, respectively (Table 8h). 
In the all group, as well, both the baseline and follow-up score Is and score4s were 
significantly higher among those with greater than 34 nevi. The actual means were 7.4 [A] 
and 8.3 [A] as compared to 6.2 [B] (for the baseline scorels), 7.9 [A] and 8.2 [A] as 
compared to 6.5 [B] (for the follow-up scorels), 22.7 [A] and 23.3 [A] as compared to 20.1 
[B] (for baseline score4s), and finally, 23.5 [A] and 23.5 [A] as compared to 21.2 [B] (for 
follow-up score4s), for those with 34-66, greater than 67, and 0-33 nevi, respectively. In 
contrast, in the all group, 27 (53%) subjects with 0-33 nevi, as compared to 8 (36%) and 3 
(25%) of those with 34-66 and greater than 67 nevi, respectively, had increased scorels 
(p=0.051—borderline significance); (Table 8h). 
• The analysis of knowledge as a function of the subjective, self-reported nevus count 
revealed fewer significant differences within the groups. In general, for all the groups, those 
with reportedly 34-66 nevi most often had the highest knowledge means. Those who 
reported greater than 67 nevi had the highest means second most frequently. Also, those 
who recounted greater than 67 nevi predominantly had the greatest mean improvements. 
Moreover, those who believed in having either 34-66 or greater than 67 nevi tended to have 
the largest proportion of subjects with increased scores. In most instances, however, these 
differences were not significant (Table 8i). 
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In the melanoma group, mean score2 improvements were significantly higher in those 
reporting greater than 67 nevi, at 1.1 [A], as compared to 0.4 [B] and 0 [C] for those 
reporting 0-33 and 34-66 nevi, respectively. In the nevus group, the mean score 1 
improvements were significantly higher in those reporting greater than 67 nevi (0.7 [A]), as 
compared to those reporting 0-33 (-0.8 [C]) and 34-66 nevi (-0.3 [B]). Also, in the nevus 
group, those reporting greater than 67 nevi had the highest proportions of increased score Is 
and score4s: 5 (31%) as compared to 0 and 1 (25%) for scorel, (p=0.034) and 11 (69%) as 
compared to 4 (31%) and 1 (25%) for score4, (p=0.041) in subjects with reportedly greater 
than 67, 0-33, and 34-66 nevi, respectively (Table 8i). 
• The analysis of knowledge as a function of the self-reported impression of “having 
more-than-average numbers of nevi” yielded no significant differences between those who 
held such a belief, and those who either did not have such a belief or did not know. In the 
melanoma group, there was no prevailing pattern, in that the means were at times higher 
among the “believers”, and at other times higher in the other groups. However, the total 
score4 means were highest among the “believers” at baseline, and highest among the 
“uncertain” ones at follow-up: those who were “uncertain” also had the greatest mean score4 
improvements, while the “believers” had the greatest proportion of individuals with 
increased score4s. However, none of these differences were significant (Table 8j). 
In the nevus group, the highest baseline and follow-up scores were among those who 
were “uncertain” about having greater than average nevus counts, while the greatest mean 
improvements and the greatest proportion of individuals with increased scores were 
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predominantly in the “believer” and “uncertain” categories. Again, none of these differences 
were significant (Table 8j). 
Among the controls, the “believers” tended not to have the highest scores, at either 
baseline or follow-up, but they did have the highest mean improvements, as well as the 
greatest proportion of subjects with increased scores. None of these trends were significant 
(Table 8j). 
In the PLC group, the greatest mean scores, at both baseline and follow-up, and the 
greatest mean improvements tended to occur among those who were “uncertain”. However, 
greater proportions of subjects who believed in having more nevi than average had increased 
score4s. The all group displayed a similar pattern (Table 8j). 
• The analysis of knowledge with respect to the personal history of atypical nevi (AN) 
revealed some statistically significant results. In the melanoma group, those with AN tended 
to have the highest baseline and follow-up knowledge scores, along with the highest mean 
improvements and the greatest proportion of individuals with increased scores. However, 
none of these differences were significant (Table 8k). 
The results for the nevus group could not be analyzed, given that all subjects in this 
group had a positive history of AN (Table 8k). 
In the control group, there were significant differences between the one subject with 
a documented atypical nevus, and the rest who lacked such a history. Overall, those with a 
negative AN history had higher knowledge scores at both baseline and follow-up; however, 
the subject with positive history of AN had the greatest increase in knowledge. These 
differences were significant with respect to score 1 means (0 [B] and 5.3 [A] at baseline, and 
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3.0 [B] and 6.8 [A] at follow-up, for those with and those without AN, respectively), and 
baseline score3s and score4s (6.0 [B] and 9.2 [A] (score3s) and 8.0 [B] and 18.8 [A] 
(score4s), for those with and those without AN, respectively). Also, the mean score3 
improvements were also significantly higher in the subject with positive AN (3.0 [A]), as 
compared to those without AN (0.4 [B]); (Table 8k). 
In the PLC group, the follow-up score Is and score4s were significantly higher in 
those without AN (at 7.5 [A] and 22.8 [A], respectively), as compared to the subject with AN 
(at 6.1 [B] and 21.0 [B], respectively); (Table 8k). 
In the all group, again, those with AN had significantly higher baseline and follow-up 
means as compared to those without AN. The actual means were 7.4 [A] and 5.7 [B] (for the 
baseline score Is), 7.4 [A] and 6.5 [B] (for the follow-up score Is), 5.2 [A] and 4.6 [B] (for 
the baseline score2s), 5.6 [A] and 5.1 [B] (for the follow-up score2s), 22.1 [A] and 19.5 [B] 
(for the baseline score4s), and finally, 22.7 [A] and 21.2 [B] (for the follow-up score4s) for 
those with AN those without AN, respectively. Also, those without AN had the greatest 
mean improvements, significantly so with respect to only score2 (0.1 [B] for those with AN, 
as compared to 0.8 [A] for those without AN). Also, those without AN (n=15 (50%)) had 
significantly higher proportions of subjects with increased scores, as compared to those with 
AN (n=T5 (28%)); (p=0.032); (Table 8k). 
• The analysis of knowledge as a function of a personal history of non-melanoma skin 
cancer (NMSC) yielded some significant differences. In the melanoma group, those with a 
positive NMSC history had higher (baseline and follow-up) means, as well as greater score 
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increases and higher proportions of subject with increased scores. However, none of these 
differences were significant (Table 81). 
In the nevus group, by contrast, the highest means occurred in those with a negative 
NMSC history, with significant differences in the baseline score Is (6.5 [B] and 8.0 [A] for 
those with and those without prior NMSCs, respectively), and baseline score3s (8.7 [B] and 
9.7 [A] for those with and those without prior NMSCs, respectively). Meanwhile, those with 
prior NMSC had not only greater degrees of score increase, but also greater proportions of 
individuals with increased scores. Notably, 3 (50%) subjects with, as compared to 3 (11%) 
subjects without prior NMSC had increased scorels (p=0.028); (Table 81). 
In the control group, those with prior NMSCs tended toward higher means at both 
baseline and follow-up, while those without prior NMSCs had higher proportions of subjects 
with increased scores. However, none of the differences were significant (Table 81). 
In the PLC group, those without prior NMSC tended to have higher baseline and 
follow-up means, but those with prior NMSC had greater degrees of improvement. Also, 
those with prior NMSCs had higher proportions of subjects with increased scores. Namely, 
6 (50%) subjects with prior NMSC, as opposed to only 11 (20%) subjects without prior 
NMSC, had increased scorels (p=0.035); (Table 81). 
In the all group, those with prior NMSC usually had higher means at both baseline 
and follow-up. There were no specific patterns to describe the mean score increases or the 




• The analysis of knowledge as a function of the family history of melanoma also 
revealed some significant differences. Among melanoma subjects, those who were 
“uncertain” had the highest baseline and follow-up means—significantly so in the follow-up 
score2s (6.5 [A] for those who were “uncertain”, as compared to 7.4 [B] and 6.8 [C] for those 
with a positive and negative family history, respectively). The score3 trends were an 
exception to this rule, given that those with a positive family history had higher score3 
means—significantly so at baseline (9.8 [A], 9.5 [A], and 8.5 [B] for those reporting positive, 
negative, and “uncertain” family histories of melanoma, respectively). Also, those who were 
“uncertain” of a family history of melanoma had higher degrees of score increase, as well 
as higher proportions of subjects with improved scores. However, none were significant 
(Table 8m). 
In the nevus group, the highest means and the greatest score increases occurred in 
those with either a positive or an “uncertain” family history of melanoma; however, the 
overall sum (score4) was highest in those with a positive family history. By comparison, 
those without a family history of melanoma had higher proportions of subjects with 
increased knowledge. None of these findings were significant (Table 8m). 
Among the controls, those with a family history of melanoma never had higher 
baseline knowledge scores, but at times, had greater degrees of improvement, resulting in 
higher follow-up scores. The overall score (score4) was, nonetheless, higher in those who 
were “uncertain”. The follow-up score Is were significantly higher in “uncertain” subjects, 
at 9.0 [A], as compared to 6.0 [B] and 6.2 [B] for those with and without family histories, 

66 
respectively. Also, subjects with a family history of melanoma, or “uncertain’ of it, had 
higher proportions of individuals with increased knowledge (Table 8m). 
Likewise, in the PLC group, the highest means, the greatest mean improvements, and 
the greatest proportions of subjects with increased knowledge were associated with either 
positive or “uncertain” family histories of melanoma. However, none of the differences were 
significant. The same pattern also prevailed in the all group, in which the “uncertain” 
subjects had significantly higher follow-up score Is (8.3 [A], as compared to 7.4 [B] and 6.8 
[C] in those with and without such family histories, respectively), mean improvements (1.6 
[A], as compared to 0.1 [B] and 0.2 [B] in those with and without such family histories, 
respectively), and proportions of subjects with increased score Is (6 (24%), as compared to 
6 (24%) and 18 (35%) of those reporting positive and negative family histories, 
respectively); (p=0.025); (Table 8m). 
• The analysis of knowledge as a function of the family history of non-melanoma skin 
cancers (NMSC) revealed, again, unexpected trends. In the melanoma group, the highest 
(baseline and follow-up) scores, mean improvements, and proportions of subjects with 
improved scores were observed in those reporting an “uncertain” family history of NMSC. 
There were significant differences in the mean score Is (8.2 [A], as compared to 6.8 [B] and 
6.3 [C] at baseline, and 8.7 [A], as compared to 6.6 [B] and 6.0 [B] at follow-up, for those 
reporting “uncertain”, positive, and negative family histories of NMSC, respectively), 
follow-up score2s (6.2 [A], as compared to 5.6 [A] and 5.4 [A] for those reporting 
“uncertain”, positive, and negative family histories of NMSC, respectively), and follow-up 
score4s (24.7 [A], as compared to 21.9 [B] and 20.6 [B], for those reporting an “uncertain”, 
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positive, and negative family histories of NMSC, respectively). The mean improvements for 
score3 and score4 were significantly higher in those with an “uncertain” and/or positive 
family history of NMSC (score 1 improvements of 0.3 [A] and 0.3 [A] for those with 
“uncertain” and positive family histories of NMSC, as compared to -0.5 [B] for those 
reporting no such family history, and score4 improvements of 1.5 [A], as compared to 0.5 
[B] and -0.3 [C], for those reporting “uncertain”, positive, and negative family histories of 
NMSC, respectively). Finally, all 6 (100%) subjects with an “uncertain” family history of 
NMSC, as compared to 10 (63%) and 2 (18%) of those with and without such a history, 
respectively, had increased score4s (p=0.038); (Table 8n). 
In the nevus group, the patterns were not as consistent, given that the means were 
mostly, but not always, higher in those with an “uncertain” history. All these findings were 
nonsignificant, other than the baseline score Is, which were significantly higher in those 
without a family history of NMSC (at 8.1 [A]), as compared to those with such a history or 
“uncertain” of it (at 7.5 [B] and 6.3 [C], respectively). The mean changes in knowledge were 
also usually higher in those with an “uncertain” family history of NMSC, as compared to the 
others. These were nonsignificant, except for the mean score 1 changes, which were 
significantly higher (at 1.3 [A]) in those with an “uncertain” history, as compared to 0.5 [B] 
and -0.5 [C] for those with positive and negative family histories, respectively. The highest 
proportions of increased scores also usually occurred in those with an “uncertain” family 
history of NMSC, however without statistical significance (Table 8n). 
Among the controls, in contrast, those with a positive family history of NMSC tended 
to have the highest knowledge means, the greatest mean knowledge improvements, and the 
1 
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greatest proportions of subjects with increased scores. These differences were only 
significant in relation to follow-up score2s (at 6.3 [A] for those with a positive family 
history, as compared to 4.8 [B] and 4.2 [B] for those with negative and “uncertain” family 
histories, respectively); (Table 8n). 
Among PLCs, again, those with an “uncertain” family history of NMSC usually had 
the highest means, mean improvements, and proportions of individuals with increased scores. 
These were significant only for the mean improvements in score 1 and score4—0.8 [A] as 
compared to 0 [B] and -0.4 [B] (for the score Is) and 1.4 [A] as compared to 0.6 [B] and 0 
[C] (for the score4s) for those with “uncertain”, positive, and negative family histories of 
NMSC, respectively. Finally, all 9 (100%) subjects with an “uncertain” family history, as 
compared to only 15 (56%) and 10 (33%) subjects with positive and negative such histories, 
respectively, had increased score4s (p=0.006); (Table 8n). 
In the all group, those with either positive or “uncertain” family histories of NMSC 
had higher means, mean improvements, and proportions of subjects with increased scores. 
The score 1 improvements (1.1 [A] as compared to 0.3 [B] and 0 [C]), and the proportion of 
subjects with increased score Is and score4s (9 (60%) as compared to 12 (39%) and 9 (23%) 
for the score Is, (p=0.047), and 13 (87%) as compared to 19 (61%) and 16 (40%) for the 
score4s (p=0.02) for those with “uncertain”, positive, and negative such histories, 
respectively) were statistically significant (Table 8n). 
• There were no significant differences in knowledge between new and return 
pigmented lesion clinic patients. The return patients had higher baseline and follow-up 
score Is, while the new patients had greater degrees and proportions of subjects with score 1 
. 
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improvements. The new patients, however, had higher baseline and follow-up score2s and 
score4s, along with greater degrees and proportions of subjects with improvements. Finally, 
the melanoma and PLC (baseline and follow-up) score4s were higher among return patients, 
while this was reversed in the nevus group-higher (baseline and follow-up) score4s among 
new patients. However, in all three groups, the new patients had higher degrees and 
proportions of improved score4s (Table 80). 
VI. Skin Self-Examination Practices as a Function of Demographic and Phenotypic 
Characteristics and of Melanoma Risk Factors: 
Skin self-examination (SSE) was analyzed first, by comparing the group SSEs to one 
another, and second, by analyzing the variations in SSE within each group as a function of 
demographic, phenotypic, and high-risk variables. Again, the subjects were analyzed by 
both group and clinic, while the SSEs were analyzed in the three different steps to be 
explained. The first step entailed comparing the number of times per year that each subject 
(in each group) reported to examine his/her skin—from never (0 times per year) to everyday 
(365 times per year)—and determining what variables, if any, promoted change in each 
group. In the second step, given that at the two extremes, no skin self-examinations and 
daily ones were both judged to be ineffective at detecting new melanoma lesions, an 
“optimal” skin self-examination was defined to range from once per month to once every 4 
months. Thus, the second step entailed analyzing the proportion of “optimal” SSEs within 
each group, and determining what variables, if any, promoted more “optimal” SSEs. The 
third step entailed determining differences (between and within groups) in the proportion of 
.. 
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subjects who never performed SSEs, and what variables, if any, increased the likelihood of 
change. 
• First, the SSE practices were compared by both group and clinic population. The 
SSE means (per year) were significantly different between the groups at both baseline and 
follow-up, at 49.6 [B], 18.0 [C], and 77.2 [A] at baseline, and 52.3 [B], 15.2 [C], and 76.8 
[A] at follow-up, for the melanoma, nevus, and control groups, respectively. (As observed, 
the SSE (per year) means are significantly higher among the controls, but closest to 
“optimal” in the nevus group). The mean change in SSE was minimal, with no significant 
differences in either the degree of change, or the proportion of increased SSEs between the 
groups. The results were similar for the PLC versus control populations (Table 9a). 
Significantly higher proportions of controls never performed SSEs at both baseline 
and follow-up: 4 (12%) melanoma and 3 (9%) nevus, as compared to 6 (30%) controls at 
baseline (p=0.054), and 4 (12%) melanoma, 1 (3%) nevus, as compared to 5 (25%) controls 
at follow-up (p=0.017). (The same melanoma subjects performed no SSEs at both baseline 
and follow-up). This trend also pertains to the comparison of the PLC and control 
populations, where 7(11%) PLCs as compared to 6 (30%) controls at baseline (p=0.035), 
and 5 (8%) PLCs as compared to 5 (25%) controls at follow-up (p=0.034) never performed 
SSEs. Also, higher proportions of melanoma, nevus—and by extension, PLC—subjects 
performed “optimal” SSEs at both baseline and follow-up; however, these differences were 
not significant. Also, there were no significant differences between the groups or clinics in 
the proportion of subjects with either change from “non-optimal” to “optimal” SSEs, or 
change from no SSEs to +SEEs (Table 9a). 
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• The analysis of SSE practices as a function of sex yielded almost no significant 
differences. In general, except in the controls, the males had higher SSE means (per year), 
but the female SSE means were closer to ’’optimal”. Only the nevus follow-up SSEs were 
significantly different, at 12 [B] for females and 25 [A] for males. None of the mean SSE 
changes were significant within the various groups (Table 9b). 
Meanwhile, except in the nevus group where all males reported +SSEs, lower 
proportions of females performed no SSEs at follow-up (the baseline proportions were 
mixed). None of these differences were significant. Nor were the changes from no SSEs to 
+SSEs significant (Table 9b). 
In the melanoma and control groups, more females than males performed “optimal” 
SSEs, while in the control and all groups, more males than females performed “optimal” 
SSEs, at both baseline and follow-up. Only the controls’ baseline “optimal” SSEs were 
significant, where no females, as compared to 3 (50%) males performed “optimal” SSEs 
(p=0.005). None of the changes from “non-optimal” to “optimal” SSEs were significant 
(Table 9b). 
• There were no significant age-related differences in SSE practices within the groups. 
The 18-35 year old melanoma and PLC subjects, and the greater-than-36 year old nevus 
subjects had lower, but closer to “optimal”, SSE means (per year); however, this was not 
significant. Also, the degrees and proportions of SSE increase within the groups were not 
statistically significant (Table 9c). 
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In all the groups, at both baseline and follow-up, those in the 36-50 year old age 
group had the lowest proportions of no SSEs. Neither these, nor the changes therein, were 
statistically significant in any of the groups (Table 9c). 
Also, there were no significant age-related differences in the proportions of“optimar 
SSEs, or changes therein, within the groups. Nonetheless, in general, the greatest proportions 
of “optimal” SSEs, and changes from “non-optimal” to “optimal” SSEs, were observed in 
the 18-35 or the 51-85 age groups (Table 9c). 
• The analysis of SSE practices as a function of hair color revealed few significant 
differences. In all the groups, blond/red or light brown haired subjects had higher SSE 
means (per year). However, the SSE means (per year) were close to “optimal” in only the 
nevus group. In all the groups, higher proportions of subjects with blond/red or brown/black 
hair had increased SSEs; however, this was not significant (Table 9d). 
In all the groups, at baseline, higher proportions of subjects with either blond/red or 
brown/black hair reported performing no SSEs. These had all decreased by follow-up, 
except among the controls. Significantly, in the melanoma group, at both baseline and 
follow-up, no blond/red, as compared to 1 (9%) light brown and 3 (30%) brown/black haired 
subjects reported to never perform SSEs (p=0.036). Within the groups, there were no 
significant differences relating to the color of the hair in the proportion of subjects with 
change from no SSEs to +SSEs (Table 9d). 
At baseline, in all but the melanoma group, those with light brown hair had the 
highest proportions of “optimal” SSEs. At follow-up, in all but the controls, those with 




differences were significant in the PLC group, where 13 (65%) blond/red and 9 (60%) light 
brown, as compared to 12 (39%) brown/black haired subjects had follow-up “optimal” SSEs 
(p=0.059, borderline significance). Also, in all but the control group, those with blond/red 
hair had higher proportions of individuals with change from “non-optimal” to “optimal” 
SSEs. This was significant in the PLC group, where 10 (50%) blond/red, as compared to 3 
(20%) light brown and 7 (23%) brown/black haired subjects changed from “non-optimal” 
to “optimal” SSEs (p=0.051); (Table 9d). 
• The analysis of SSE with respect to eye color yielded virtually no significant trends. 
In all groups but the all group, those with either hazel/grey or light/dark brown eyes had the 
highest SSE means (per year). In the all group (consisting of all subjects in the study), those 
with blue/green eyes had the highest baseline and follow-up SSE means (per year). 
However, only the baseline and follow-up SSE means of light/dark brown eyed melanoma 
and PLC subjects, all nevus subjects, and hazel/grey-eyed control subjects were close to 
“optimal”. Also, in all but the melanoma group, light/dark eyed subjects had the greatest 
proportions of individuals with increased SSEs. However, none of these differences were 
significant (Table 9e). 
Within most groups, at both baseline and follow-up, lower proportions of subjects 
with either hazel/grey or light/dark brown eyes reported to never perform SSE. However, 
none of these differences were significant. Nor were there significant differences relating 




Within all the groups, the eye color category with the highest proportions of “optimal’ 
SSEs shifted from a darker category of eye color at baseline, to a lighter one at follow-up. 
Among PLCs, for instance, those with hazel/grey eyes had the greatest proportion of baseline 
“optimal” SSEs, which by follow-up had shifted to both hazel/grey and blue/green eyes. 
These differences were significant in only the melanoma baseline SSEs, where 4 (67%) 
light/dark brown, as compared to 4 (19%) blue/green and 1 (17%) hazel/grey eyed subjects 
performed “optimal” SSEs (p=0.044). Meanwhile, in all but the control group, subjects with 
hazel/grey eyes had the highest proportions of change from “non-optimal” to “optimal” 
SSEs; however, none were significant (Table 9e). 
• The analysis of SSE as a function of self-reported skin reaction to acute sunlight 
yielded no significant differences between those who bum and those who tan. In the 
melanoma, control, and all groups, the tanners had higher baseline and follow-up SSE means 
(per year), while in the nevus and PLC groups, the reverse was true. Elowever, of all 
subjects, only nevus patients who burned had close to “optimal” SSE means. In all but the 
control and all groups, those who burned had higher proportions of increased SSEs as 
compared to the tanners. Elowever, none of the above differences were significant (Table 
90- 
In all but the melanoma group, higher proportions of burners had reported to never 
perform SSEs at baseline. However, by follow-up, in the melanoma, nevus, and PLC groups 
(but not the control and all groups), lower proportions of burners reported performing no 
SSEs. However, neither the baseline and follow-up differences, nor the proportions of 
subjects with change from no SSEs to +SSEs, were statistically significant (Table 9f). 
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In the melanoma and PLC groups, higher proportions of burners performed “optimal” 
SSEs at both baseline and follow-up, while the reverse held true for the nevus, control, and 
all subjects. Also, in all but the controls, those who burned had greater proportions of change 
from “non-optimal” to “optimal” SSEs. However, none of these differences were significant 
(Table 9f). 
• The analysis of SSEs as a function of the self-reported inability to tan also revealed 
no significant differences. In all the groups, at both baseline and follow-up, those who could 
not tan in response to chronic sun-exposure (i.e., those who freckled or developed a mild tan 
following several peelings) had higher SSE means (per year). However, only nevus subjects 
(both frecklers and tanners) had close to “optimal” SSE means. Meanwhile, in all the 
groups, the tanners had higher proportions of increased SSEs. Again, none of these 
differences were significant (Table 9g). 
In all but the baseline nevus and follow-up control groups, lower proportions of 
frecklers than tanners reported never performing SSEs. However, neither these baseline and 
follow-up proportions, nor the proportions of change from no SSEs to +SSEs were 
significant (Table 9g). 
At baseline, in all but the melanoma group, higher proportions of tanners performed 
“optimal” SSEs; however, at follow-up, in all but the control group, higher proportions of 
frecklers performed “optimal” SSEs. In all but the controls, the frecklers had higher 
porportions of change from “non-optimal” to “optimal” SSEs. However, none of these 
differences were significant (Table 9g). 
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• The analysis of SSEs as a function of the objective, physician-determined nevus 
count revealed some significant differences. In all the applicable groups—melanoma, nevus, 
PLC, and all, but not control, given that all controls had 0-33 nevi—subjects with greater than 
67 nevi had the highest SSE means (per year) at both baseline and follow-up. However, only 
the melanoma baseline SSEs were significantly different, at 46.9 [B], 27.4 [C], and 141.3 [A] 
for those with 0-33, 34-66, and greater than 67 nevi, respectively. Also, the only close to 
“optimal” SSE means pertained to melanoma subjects with 34-66 nevi at follow-up, nevus 
subjects with 0-66 nevi at both baseline and follow-up, PLC subjects with 34-66 nevi at 
follow-up, and all subjects with 34-66 nevi at follow-up. However, none of these differences 
were significant. Meanwhile, in all the groups, subjects with 0-33 nevi had the greatest 
proportions of increased SSEs, however, without statistical significance (Table 9h). 
In all groups (but the nevus group at follow-up), at both baseline and follow-up, a 
higher proportion of subjects with 0-33 nevi reported never performing SSEs. These 
differences were significant in the nevus group, where 3 (25%), 0, and 0 (at baseline, 
p=0.040), and 0, 0, and 1 (11%) (at follow-up, non-significant p) subjects with 0-33, 34-66, 
and greater than 67 nevi, respectively, reported never performing SSEs. In this group, the 
proportions who changed from no SSEs to +SSEs were significant: 3 (25%), 0, and 0 
subjects with 0-33, 34-66, and greater than 67 nevi, respectively (p=0.040). Also, the 
baseline proportions of PLC and all subjects who reported never performing SSEs were 
significantly different, at 7 (22%), 0, and 0 (for the PECs, p=0.011), and 13 (25%), 0, and 
0 (for the all group, p=0.004) for those with 0-33, 34-66, and greater than 67 nevi. 
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respectively. However, the change from baseline to follow-up was not significant for these 
groups (Table 9h). 
In all but the nevus group (at follow-up), subjects with 34-66 nevi had the highest 
proportions of “optimal” SSEs at both baseline and follow-up. Also, in all but the nevus 
group, those with greater than 67 nevi had the greatest proportions of change from “non- 
optimal” to “optimal” SSEs. In the nevus group, those with 0-33 nevi had the greatest 
proportions of change from “non-optimal” to “optimal” SSEs. However, none of these 
differences were significant (Table 9h). 
• The analysis of SSE as a function of the subjective, self-reported nevus count yielded 
some significant differences. Melanoma, PLC, and all subjects reporting 34-66 nevi, and 
nevus subjects reporting greater than 67 nevi had the highest SSE means (per year). 
Meanwhile controls who recounted 0-33 and greater than 67 nevi at baseline, and those who 
reported 0-33 nevi at follow-up, had the highest SSE means (per year). There were 
significant differences in the melanoma and PLC follow-up SSEs as a function of the 
subjective nevus count: the SSE means (per year) were 15.3 [C], 131.4 [A], and 73.7 [B] 
(for melanoma), and 13.9 [B], 89.8 [A], and 34.5 [B] (for PLC) subjects reporting 0-33, 34- 
66, and greater than 67 nevus categories. These SSE means were close to “optimal” in only 
melanoma and PLC subjects reporting 0-33 nevi (at both baseline and follow-up), almost all 
nevus subjects (at both baseline and follow-up), and controls reporting greater than 34 nevi 
(at follow-up only). However, none of these were significant. Meanwhile, in all but the 
control group, the mean increase in SSE was highest in those recounting 34-66 nevi, with 
significant differences in the all group, at 0.8 [B], 23.6 [A], and -13.4 [C] for controls 
. 
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reporting 0-33, 34-66, and greater than 67 nevi, respectively. Also, in all groups, those 
reporting either 0-33 or 34-66 nevi had the greatest proportions of increased SSEs. These 
were significant only in the nevus group, where 8 (62%), 1 (25%), and 4 (25%) subjects 
reporting 0-33, 34-66, and greater than 67 nevi, respectively, had increased SSEs (p=0.051); 
(Table 9i). 
In all but the control group, those recounting 0-33 nevi had higher proportions of 
subjects who never performed SSEs at baseline. This was significant in the nevus and all 
groups, where 3 (23%), 0, and 0 (nevus, p=0.036) and 11 (22%), 1 (8%), 1 (4%) (all, 
p=0.031) subjects reporting 0-33, 34-66, and greater than 67 nevi never performed SSEs. 
By follow-up, this significance had dissipated in both groups; however, only the change from 
no SSEs to +SSEs in the 3 (23%), 0, and 0 atypical nevus subjects who reporting 0-33, 34- 
66, and greater than 67 nevi, respectively, was significant (p=0.036). Moreover, at follow¬ 
up, only those who reported 34-66 nevi had a 100% +SSE rate (Table 9i). 
In all but the control group, those reporting 34-66 nevi had the highest proportions 
of “optimar baseline SSEs. At follow-up, in all groups, subjects recounting greater than 67 
nevi had increased proportions of “optimal” SSEs; however, subjects reporting 0-33 nevi had 
the greatest proportion changes from “non-optimal” to “optimal” SSEs—however, none of 
these findings were significant (Table 9i). 
• The analysis of SSEs as a function of the subjective impression of having more-than- 
average nevi yielded some significant trends. In general, those who believed in having more- 
than-average nevi had the highest SSE means (per year), at both baseline and follow-up. 
These SSE means were close to “optimal” in almost all nevus subjects (at both baseline and 
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follow-up), “uncertain” control and all subjects (at baseline), and “non-believing” and 
“uncertain” PLCs (at follow-up). None of these findings were significant. Also, in all but 
the melanoma group, “uncertain” subjects had the greatest proportions of increased SSEs, 
with significant differences in the nevus group, where 7 (30%), 4 (40%), and 2 (100%) 
subjects believing in, not believing in, or “uncertain” of having more-than-average nevi had 
increased SSEs (p=0.051, borderline significance); (Table 9j). 
Subjects “uncertain” of having more-than-average nevi had significantly higher 
proportions of no SSEs, while the “believers” had significantly lower proportions of no 
SSEs: 0 as compared to 2 (13%) and 2 (40%) melanomas (at both baseline and follow-up, 
p=0.029), 1 (4%) as compared to 1 (13%) and 1 (50%) nevus (at baseline, p=0.032), 1 (3%) 
as compared to 3 (13%) and 3 (43%) PLCs (at baseline, p=0.002), and 1 (3%) as compared 
to 2 (8%) and 2 (29%) PLCs (at follow-up, p=0.021), 2 (5%) as compared to 7 (18%) and 
4 (44%) of all (at baseline, p=0.004), and 2 (5%) as compared to 5 (13%) and 3 (33%) of all 
(at follow-up, p=0.021) subjects who believed in, did not believe in, or were “uncertain” of 
having more-than-average nevi reported to never perform SSEs. From baseline to follow-up, 
there was a loss of significance in the nevus group, and a reduction in significance in the 
PLC and all groups. However, only in the nevus group were the proportions of changes from 
no SSEs to +SSEs significant: 1 (4%), 1 (13%), and 1 (50%) subjects in the respective 
groups (p=0.032); (Table 9j). 
At baseline, in all the groups, subjects reporting either average nevus counts, or 
“uncertainty” about having more-than-average nevi had the highest proportions of “optimal” 
SSEs. By follow-up, those reporting average nevus counts had the highest proportions of 
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“optimal” SSEs (all groups but the controls), and the highest porportions of change from 
“non-optimal” to “optimal” SSEs (all groups). However, none of these differences were 
significant (Table 9j). 
• The analysis of SSEs with respect to the personal history of atypical nevi (AN) 
yielded some significant results. In all but the all group, subjects with AN had higher SSE 
means (per year) at both baseline and follow-up. In the control group, the SSE means (per 
year) were significantly higher for the one subject with AN (at 365 [A] at both baseline and 
follow-up) as compared to those without AN (at 62 [B] at both baseline and follow-up). 
However, only the nevus (baseline and follow-up) SSE means approached an “optimal” SSE. 
Also, in all groups (except for the controls), the mean increase in SSE and the proportions 
of increased SSEs were greatest in those with AN. However, none of these differences were 
significant (Table 9k). 
In all the groups, those with AN had lower proportions of subjects who never 
performed SSEs. These were significant for the baseline and follow-up SSEs in the PLC and 
^//groups: 4 (7%) AN as compared to 3 (27%) non-AN PLCs (at baseline, p=0.051), 2 (4%) 
AN as compared to 3 (27%) non-AN PLCs (at follow-up, p=0.007), and 4 (7%) AN as 
compared to 9 (30%) non-AN all subjects (at baseline, p=0.005), and 2 (4%) AN and 8 
(27%) non-AN all subjects (at follow-up, p=0.002) reported never performing SSEs. As 
observed, the differences within these groups are heightened from baseline to follow-up (as 
suggested by the lower, more significant p-value). However, the proportion of changes from 
no SSEs to +SSEs were not significant in any of the groups (Table 9k). 

81 
In all but the control group, those with AN had higher proportions of “optimal” SSEs 
at both baseline and follow-up, as well as greater proportions of change from “non-optimal” 
to “optimal” SSEs. However, none of these differences were significant (Table 9k). 
• The analysis of SSEs with respect to the personal history of non-melanoma skin 
cancer (NMSC) revealed almost no significant differences. Melanoma, nevus, and therefore, 
PLC subjects without prior NMSC, and control and all subjects with prior NMSC had the 
highest baseline SSE means (per year). By follow-up, in all the groups, those with prior 
NMSC had the highest NMSC means (except in the nevus group), and the greatest mean SSE 
increases (except in the control group). However, in all groups, those without prior NMSC 
had the greatest proportions of increased SSEs. However, none of these findings were 
significant (Table 91). 
Melanoma and PLC subjects with prior NMSC, and control and all subjects without 
prior NMSC had higher proportions of subjects who never performed SSEs, at both baseline 
and follow-up. In the nevus group, subjects with prior NMSC at baseline, and those without 
prior NMSC at follow-up, had higher proportions of no SSEs. Neither these differences, nor 
the proportions of changes from no SSEs to +SSEs, were significant (Table 91). 
In all but the melanoma and control groups, those with prior NMSC had higher 
proportions of “optimal” SSEs. The controls with prior NMSC, however, had significantly 
lower proportions of optimal SSEs: 0 controls with, as compared to 2 (13%) controls without 
prior NMSC performed baseline “optimal” SSEs (p=0.015). This significance had dissipated 
by follow-up. Also, higher proportions of melanoma and control subjects with, and nevus, 
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PLC, and all subjects without prior NMSC changed from “non-optimal” to “optimal” SSEs, 
however, none with statistical significance (Table 91). 
• The analysis of SSEs as a function of the family history of melanoma yielded few 
significant findings. Surprisingly, in all but the nevus group, those with either a negative or 
an “uncertain” family history of melanoma (FHM) had higher (baseline and follow-up) SSE 
means (per year). In the nevus group, ip contrast, those with a +FHM had higher (baseline 
and follow-up) SSE means (per year). The SSE means were close to an “optimal” SSE in 
melanoma subjects with +FHM (both baseline and follow-up), almost all nevus subjects, 
regardless of FHM, PLC and all subjects with +FHM (at follow-up only), and control, PLC, 
and all subjects with an “uncertain” FHM (at follow-up only). However, none of these 
findings were significant. Also, in most groups, those with a negative FHM had the highest 
mean SSE increases—with significant differences in the all group, where the mean SSE 
changes were -3.4 [B], 6.5 [A], and -29.1 [C] for subjects with a positive, negative, and 
“uncertain” FHMM, respectively. Also, in all the groups, those with +FHMs had higher 
proportions of increased SSEs. These were significant in the PLC group (12 (52%) subjects 
with positive, as compared to 13 (35%) and 0 subjects with negative and “uncertain” FHMs, 
respectively (p=0.026)) and the all group (13 (52%) subjects with positive, as compared to 
17 (33%) and 1 (11%) subjects with negative and “uncertain” FHMs, respectively had 
increased SSEs (p=0.054, borderline significance)); (Table 9m). 
Except in the nevus and control groups, those with a +FHM had lower proportions 
of never performing SSEs at baseline. Interestingly, at follow-up, none of the subjects with 
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a +FHM reported never performing SSEs. However, neither these findings, nor the 
proportions of changes from no SSEs to +SSEs were significant (Table 9m). 
At baseline, in only the melanoma group did those with a +FHM have the highest 
proportion of baseline “optimal” SSEs. At follow-up, in all but the nevus group, those with 
a +FHM had the highest proportions of “optimal” SSEs. Also, in all but the melanoma and 
nevus groups, those with a +FHM had the greatest proportions of change from “non-optimal” 
to “optimal” SSEs. However, none of these findings were significant (Table 9m). 
• The analysis of SSEs as a function of the family history of non-melanoma skin cancer 
(FFfNMSC) yielded a few significant differences. In the melanoma, nevus, and PLC groups, 
those with a +FHNMSC had higher (baseline and follow-up) SSE means (per year), while 
in the control and all groups, higher means were observed in those with “uncertain” 
FHNMSCs. SSE means close to an “optimal” were observed in melanoma subjects with an 
“uncertain” FHNMSC (at follow-up), almost all nevus subjects (at both baseline and follow¬ 
up), controls with +FHNMSC (at follow-up), and PLCs with an “uncertain” FFINMSC (at 
follow-up). However, none of these findings were significant. In only the melanoma and 
PLC groups did those with a +FHNMSC have the greatest SSE increases. Meanwhile, 
controls with a negative FHNMSC had significantly higher mean increases in SSE, at 22.6 
[A], as compared to -58.8 [C] and 0 [B] for those with positive and “uncertain” FHNMSCs, 
respectively. Meanwhile, in all but the melanoma group, those with negative FHNMSCs had 
the highest proportions of increased SSEs. These proportions were significantly different 
in the melanoma and all groups (8 (50%), 4 (36%), and 0 melanoma (p=0.036), and 12 
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(39%), 17 (43%), and 2 (13%) all (p=0.054, borderline significance) subjects with positive, 
negative, and “uncertain” FHNMSCs had increased SSEs (Table 9n). 
In all groups, lower proportions of subjects with +FHNMSCs reported performing 
no SSEs at both baseline and follow-up. Flowever, neither these differences, nor the 
proportions of changes from no SSEs to +SSEs were significant (Table 9n). 
In only the control group did subjects with +FHNMSCs have the highest proportions 
of “optimal” SSEs (at both baseline and follow-up). Moreover, melanoma and control 
subjects with +FHNMSCs, and nevus, PLC, and all subjects with negative FHNMSCs had 
the highest proportions of change from “non-optimal” to “optimal” SSEs. However, none 
of these findings were significant (Table 9n). 
• Analysis of SSEs with respect to the number of previous visits to the pigmented 
lesion clinic yielded interesting results. Return melanoma, but new nevus patients had the 
highest SSE means (per year) at both baseline and follow-up. These were significant in the 
nevus baseline SSEs, at 50 [A] for new, and 20 [B] for return subjects. Only the return nevus 
patients had close to “optimal” SSE means. Meanwhile, higher proportions of new 
melanoma and return nevus patients had increased SSEs. However, none of these findings 
were significant (Table 9o). 
In both groups, lower proportions of return patients reported never performing SSEs 
by follow-up. These were significant in the nevus group, where 1 (17%) new, as compared 
to no return patient reported never performing SSEs (p=0.034). The changes from no SSEs 
to +SSEs were not significant (Table 9o). 
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In both groups, higher proportions of return patients reported “optimal” SSEs (at both 
baseline and follow-up), while greater proportions of new patients changed from “non- 
optimal” to “optimal” SSEs. However, none of these findings were significant (Table 9o). 
VII. Optimal Skin Self-Examination of Various Body Zones & Examination with a 
“Buddy”: 
The final stage of analysis entailed comparing the groups’ examination of different 
body zones and the use of a “buddy” (Table 10). The subjects were, again, analyzed by both 
group and clinic; however, given that only the clinic-related results revealed significant 
differences, only those were included in the table. Also, an “optimal” examination frequency 
was defined, given that both extremes of SSE (either no or daily SSEs) would be undesirable. 
An “optimal” SSE ranged in frequency from once per month to once every 4 months, except 
in relation to non-traditional areas such as the scalp and genitals, for which the “optimum” 
was defined to range from once per month to once per year-given that they would probably 
be examined less frequently, given their difficult-to-examine locations. Thus, for the genitals 
and scalp to be self-examined at least once per year was considered to be a significant 
indicator of skin-awareness (Table 10). 
There were no significant differences between the proportions in each clinic 
“optimally” using a “buddy” to examine difficult-to-see areas. There were, however, 
significant differences in the proportions in each clinic population performing “optimal” SSE 
of the front (30 (45%) PLCs as compared to 4 (20%) controls, p=0.043), sides (32 (48%) 
PLCs as compared to 3 (15%) controls, p=0.008), and the back (30 (45%) PLCs as compared 
to 6 (30%) controls, p=0.043). There differences in the proportions in each clinic population 
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performing “optimal” SSEs of areas such as the scalp and genitals were not significant. The 
controls’ SSE means were significantly higher than that of the PLCs with respect to the 
examination of the sides (127 [A] as compared to 48 [B]) and such areas as the scalp and 
genitals (84 [A] as compared to 15 [B]). However, these PLC SSE means were closer to the 




I. Discussion of Results: 
Potential Sources of Bias: The principle task in interpreting the study results would 
be to identify all possible sources of bias. Some of the biases in this study pertained to the 
patient population, while others related to the questionnaire design. These biases will be 
systematically addressed in the following section. 
• Biases in the Patient Population: First, the study participants were primarily recruited 
through university dermatology clinics at Yale. Most of the subjects were of middle- to 
upper-middle class SES, and therefore, higher educational levels, given that greater than 70% 
of them had (at least) semi-professional careers. This was expected from a population of 
Connecticut residents being followed by academic physicians at a university-based medical 
center. As this was a potential source of bias—given the documented association between 
high education levels and better health awareness and health practices~it was attempted to 
rectify the situation by recruiting patients through a hospital-based dermatology clinic (with 
mostly Medicaid patients). However, the enrollment efforts met with very low yield at the 
hospital-based clinic, given that most of the approached patients refused to participate; this 
differed starkly from the university-based dermatology clinics, where almost all the 
approached patients readily consented to partipating in the study. Moreover, of the three 
hospital general dermatology clinic patients who did consent to participating in the study 
(and completed the study), one reported a family history of melanoma and one was 
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consulting about pregnancy-related changes in pre-existing melanocytic nevi. These raise 
the issue of self-selection bias, which is inherent to this study design. 
Second, the study controls were a population of general dermatology patients. In 
retrospect, this probably biased the analysis of skin self-examination (SSE) practices, given 
that, in this population, there was no means of differentiating between skin examination for 
signs of dermatologic diseases like psoriasis and sarcoidosis, and signs of potential 
melanoma lesions. (Perhaps the anticipation of this dilemma at the onset would have 
allowed the modification of the questionnaire to elicit such differences, or else, the selection 
of a general medicine patient population, with no confounding dermatologic diseases, as 
controls. But as such was not the case, the effects of this bias would remain unknown). 
Third, given that this was a pilot study, with a consequently small population size, 
variables which could have been significant predictors of change in knowledge and SSE with 
a larger sample size, may have appeared to be non-significant in our analyses. 
• Questionnaire-Based Biases: Knowledge of the subjects’ risk factor profiles relied 
solely on their self-reports. Whereas in many cases (such as with eye and hair colors) the 
categories were straight-forward, and therefore, not subject to recall or self-report bias, in 
other cases (such as acute and chronic skin reactions to sunlight), this might not have been 
so. For example, subjects might have reported not burning in reaction to acute sun-exposure 
because of wearing sunscreen or avoiding excessive sun-exposure, as opposed to basing their 
responses on their natural skin tendencies. 
Second, the questionnaires examined the subjects’ awareness of several melanoma 
facts that were not addressed in the educational video. The rationale behind incorporating 
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these questions into the questionnaires, despite our awareness of this flaw, was that this pilot 
study had been performed in the past with an educating nurse as opposed to the video, and 
therefore, it was important to maintain as much constancy as possible between the studies, 
in order to be able to compare their efficacy of the two educational media or tools in 
promoting change in knowledge and behavior. 
Third, there was no means of verifying the self-reported SSE frequencies, which 
could have been inflated due to an awareness of the study messages regarding melanoma and 
the importance of early detection through regular SSEs. Of note, the follow-up questionnaire 
had two questions on the frequency of general body SSEs, one at the beginning and another 
at the end of the questionnaire. Lower proportions of individuals reported never performing 
SSEs in response to the second question, as compared to the first one. Since the responses 
to the first question were more likely to be accurate, they were used in the analyses so as to 
minimize bias. 
Finally, in both the pre- and post-questionnaires, the subjects were asked whether 
they conducted careful, directed examinations of their skin, in order to assess their SSE 
practices. In retrospect, it would have been useful to also ascertain how carefully they 
performed SSEs—i.e., what they meant by a “careful and directed” exam. In one study, four 
definitions of self-surveillance were used, consisting of (1) a general awareness, both 
cosmetic and medical (although it might be more useful to separate these); (2) purposeful 
examination of regions of the body (which was addressed in our study at follow-up); (3) the 
observation of a particular mole; and (4) surveillance by a spouse or “buddy” [30]. 
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Discussion of Results: Having a grasp of the areas of melanoma awareness versus 
deficit in each population would be critical to the design of any educational interventions and 
campaigns. The melanoma and nevus (or PLC) groups represent a population which, given 
its high risk of melanoma, has been actively targeted by physicians with not only regular 
surveillance, but also education and behavior modification interventions. Therefore, such 
a population would have a much higher understanding of melanoma risk factors and 
characteristics. In contrast, the control group, a population at lower risk for melanoma, with 
probably no prior history of active interventions against melanoma, would constitute a group 
whose knowledge base would most likely reflect public education efforts through the popular 
media. These differences in knowledge would by necessity translate into different needs, 
which would have to be addressed in any intended intervention—i.e., the campaign focus for 
each population should be guided by its knowledge deficits. 
In this study, the controls were highly suspicious of changing (whether in color, size, 
shape, or thickness) and non-healing lesions, and those that were dark or variegated in color. 
That these melanoma signs would appear most alarming to a lay person makes sense. The 
popular media has already identified melanoma as being black or dark in color; and change 
(implying active growth) and poor healing are probably features frequently associated with 
cancer. Meanwhile, in all the groups, there was an overall low awareness of the somatic 
symptoms (like itching and tenderness) and size criteria of early melanoma. These 
melanoma signs and symptoms represent potential areas of deficit for focusing future 
educational interventions, especially where it concerns the early self-detection of melanoma. 
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There was also a generalized lack of awareness about alternate methods of examining 
difficult-to-see areas of the body, as in using a “buddy” or a mirror. This is an area of 
growing importance given the recent trends in melanoma epidemiology—for instance, the 
back is the most common and the second-most common site for development of melanoma 
in men and women, respectively. It assumes even greater significance in view of the finding 
that women tend to find their own lesions regardless of the location, whereas men rarely 
discover a lesion on the back [185]. In our study, at baseline, all groups (and especially the 
controls) were poorly aware of how to survey difficult-to-see skin surfaces, like the back. 
However, the intervention significantly improved subjects’ awareness regarding this area. 
Thus, it appears that this is also an important area for focusing future public intervention 
efforts. 
Meanwhile, all three groups had nearly identical knowledge levels about melanoma 
risk factors, perhaps reflecting the growing media focus on melanoma, concomitant with the 
AAD screening campaigns over the past decade. Given this context, the subjects’ high 
awareness of high-risk phenotypes like red hair, blue eyes, and a tendency to bum, were 
understandable. However, the high awareness of the association between melanoma and 
either atypical nevi or high numbers of CAMN was surprising, given that they have received 
relatively little media attention. This seemingly high awareness of high nevus counts and 
atypical nevi as melanoma risk factors might be either tme, or subtly (and unpredictably) 
influenced by cues in the phrasing of the questions (as in ‘Wd-shaped moles”), leading the 
subjects to the correct answer. Regardless of this point, future public education interventions 
should devote greater attention to these significant melanoma risk factors, so that at-risk 
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individuals can appropriately ascertain their own risk, and (hopefully) attend AAD annual 
screenings and adopt more self-screening and sun-safe behaviors. 
The data revealed the subject group to be one of the most important predictors of 
knowledge levels, as well as knowledge improvement: despite lower scores, the controls had 
the greatest knowledge improvement. The intervention either directly caused this increased 
awareness, or raised the subjects’ awareness of melanoma as a public health hazard, thereby 
indirectly leading them to pay greater attention to public health messages about it in the 
media. Regardless of whether the increase in knowledge was achieved directly or indirectly, 
one of intervention’s goals—i.e., to raise awareness about melanoma—was accomplished. 
This is significant, given that it documents the efficacy of such targeted educational 
interventions in raising public awareness about melanoma risk factors and clinical 
characteristics. A video such as the one used in this study could be distributed to physicians 
everywhere—including pediatricians, internists, surgeons—and shown in the waiting rooms, 
to various industries for employee education, etc. Moreover, in such small targeted 
populations, the educational tools such as the video may be tailored to the special needs and 
circumstances of the population, which would probably result in even greater yields. For 
instance, a video distributed to pediatricians, in emphasizing the role of early childhood and 
adolescence sunburns in determining later risk of melanoma, would (inadvertently) alter their 
own attitudes toward and behaviors in the sun. 
Other important predictors of knowledge scores and/or knowledge increase included 
hair color (significantly higher mean improvements and proportions of increased scores in 
those with red or blond hair); the objective, physician-determined nevus count (significantly 
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higher scores in those with either 34-66 or greater than 67 nevi); the personal history of 
atypical nevi (with usually significantly higher post-intervention knowledge means in those 
with AN); and surprisingly, the family history of non-melanoma skin cancer (with a tendency 
toward significantly higher knowledge scores and proportions of score increase in those with 
either a positive or an uncertain family history of non-melanoma skin cancer). In terms of 
knowledge score percentiles, of course, the pigmented lesion clinic population consistently 
had significantly higher proportions of individuals answering greater than 75% of the 
questions correctly at both baseline and follow-up. 
With respect to the reported SSE practices, I found the absolute frequency of SSE 
(which ranged from 0 for no exams, to 365 for daily ones) reported by the subjects less 
useful a guide to their skin-awareness and self-screening. In general, however, the atypical 
nevus group’s SSE means were more consistently near the defined “optimal” range of once 
per month to once every 4 months. Nonetheless, a subject’s group (or clinic affiliation) was 
a significant predictor of whether he/she performed no SSEs. Red or blond hair color was 
a significant predictor of both “optimal” and +SSEs, as well as of change from “non- 
optimal” to “optimal” SSEs. Both the objective, physician-determined and the subjective, 
self-reported nevus counts were significant predictors of +SSEs (given that almost all PLCs 
physician- or self-reported nevus counts exceeding 33 nevi reported +SSEs at baseline). Yet 
another predictor of +SSEs was the self-reported impression of having more-than-average 
nevus counts (this subgroup had significantly higher proportions of +SSEs at both baseline 




The lack of significant differences with respect to the rate of “optimal” SSEs, as well 
as other SSE-related measures, might reflect the simple truth about the complexities of 
behavioral modification. It is well-recognized that inducing behavioral change is a much 
more demanding task than that of enhancing knowledge. It may be that an intervention much 
more intensive than our ten-minute instructional video was needed to motivate individuals 
to perform monthly SSEs. 
II. Discussion of Strategies: 
Theoretical Considerations in Education and Screening Campaigns: 
Given the discussed trends in the epidemiology of melanoma and the body of 
information available on its risk factors, our first strategy toward melanoma control must be 
primary prevention through education and behavior modification, so as to reduce melanoma 
incidence (and therefore, mortality) through risk factor modification. The next strategy 
would be secondary prevention through early detection and diagnosis, in hopes of reducing 
melanoma mortality by intervening at an earlier, potentially more curable stage in its natural 
history [144], As discussed earlier, one major advantage of melanoma, as compared to other 
malignancies, pertains to its cutaneous, readily-visible location, which allows for ready 
detection of thinner, prognostically more favorable lesions [144]. Moreover, given its 
uniquely visible, cutaneous location, one may consider its early detection to be inextricably 
intertwined with education about it [189], given that greater melanoma awareness could 
increase the likelihood of participation in screening efforts—including self-screening—while 
engaging in various screening efforts would heighten one’s awareness about melanoma. 
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Theoretically, education and early detection should decrease melanoma morbidity 
and mortality [182], However, as of yet, no formal prospective, randomized trials (which 
would constitute the gold standard for evaluating such interventions) have attempted to test 
the efficacy of such programs in reducing melanoma mortality [144, 187]. Moreover, that 
such a trial would ever be undertaken seems very unlikely, given that it would present many 
logistic and practical difficulties [190]. Nonetheless, melanoma prevention and control 
efforts have begun in many nations around the world over the past decade [70, 80, 101, 199, 
235, 261]. These programs have varied in scope and intensity among nations, and include 
nationwide public and professional education campaigns focusing on sun-safe behavior in 
Australia; regional professional and public education programs in Italy, the United Kingdom, 
and Austria; local screening efforts in the Netherlands and New Zealand; and national 
screening efforts in the United States [190]. 
Complicating the evaluation of these efforts are data from a collaborative study of 
cases from Alabama, U.S.A. and New South Wales, Australia [13], along with data from the 
Netherlands [81], Germany [122], Israel [315], and the United Kingdom [360], which 
suggest a trend toward improved survivals and reduced mean Breslow depths at diagnosis, 
with the trends predating the interventional efforts in these countries [190]. For instance, the 
evaluation of the King College Hospital 1986-1987 public education campaign [360], which 
entailed reviewing all melanoma specimens from 1970 to 1987, traced the greatest decrease 
in tumor thickness to the late 1970's, when the median Breslow depth fell from 
approximately 4 mm to 1.5 mm. This was accompanied by a concomitant increase in the 
proportion of thin lesions (<1.5 mm) and a decrease in both the proportion and the absolute 
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number of thick lesions (>3.5 mm), while the proportion of lesions of intermediate Breslow 
depth (1.5 mm to 3.49 mm) remained relatively stable. Also, the investigators noted an 
increase in the proportion of superficial spreading melanomas and a decrease in the 
proportion of nodular melanomas throughout the same 18-year period, with little alteration 
in this pattern during the campaign years [360]. 
Another critical issue complicating the evaluation of these education and screening 
interventions, and ultimately, of melanoma control, relates to the questionable accuracy of 
the documented melanoma diagnoses and incidences. This problem, which results from the 
increasing trend toward diagnosis and treatment of melanoma on an outpatient basis, has 
been escalating over the previous years. Increasingly, cases are not reported to central 
registries, leading to falsely lower incidence rates [190]. Two studies from Massachusetts 
and western Washington State indicated under-reporting rates of 12%-19% and 21%, 
respectively [174, 183]. 
Despite these limitations, and given the obstacles against a prospective, randomized 
trial, by necessity, the focus has shifted onto intermediate-term outcome measures as means 
of evaluating education and screening programs [308]. To this end, some of the 
intermediate-term measures for monitoring the efficacy of melanoma education could 
include: change in knowledge among target populations; increased public awareness of 
significant risk factors and one’s own susceptibility; skin self-examination (SSE) rates 
among high risk individuals; requests for physician skin examinations; and practitioners’ 
knowledge of melanoma risk [190]. In this respect, it is hoped that a change in knowledge 
would translate into improved attitudes and promote behavioral change through both primary 
' 
97 
prevention (as with altering one’s sun exposure behavior), and early detection outside of 
organized screening (as with increased skin self-examination (SSE)) [190], 
For instance, a recent U.S. study of 502 whites older than 50 years in age revealed 
an inadequate frequency of SSE among the subjects, despite high awareness of melanoma 
and its risk factors in 74% of the subjects [247]. The same study revealed both knowledge 
and preventive practices to be significantly worse among men and those without higher 
education. Only 19% of those with just a high school degree or less, as opposed to 29% of 
those with a college degree, had ever requested a physician skin examination (p <0.05). 
Likewise, only 46% of those with just a high school degree or less, as compared to 65% of 
those with a college degree had ever received a physician skin examination (p <0.05). 
Professional education of medical providers should also help optimize screening and 
thereby enhance early melanoma detection. Few medical professionals receive specific 
education and training in the early detection of melanoma. In one study, only 12% of non¬ 
dermatologists and 69% of dermatologists could correctly identify at least five of six 
melanoma lesions [51]. To this end, major professional education efforts have been 
implemented in Australia, Austria, and Scotland [190]. Australians have targeted medical 
school curricula, emphasizing primary care practitioners’ ability to detect high risk 
individuals within routine medical practice, implement opportunistic screening, and develop 
targeted screening for high risk persons [316]. In Austria (1988), all surgeons (n=900), 
dermatologists (n=350), and general practitioners (n=9000) received illustrated folders and 
publications about pigmented lesions [261]. In Scotland (1985) media and poster/leaflet 
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publicity efforts were preceded by preparing general practitioners with specially prepared 
booklets entitled “An Illustrated Guide to Early Malignant Melanoma” [80]. 
Intermediate measures of successful screening efforts could include: lower numbers 
and proportions of thick tumors in screened populations; thinner tumors in the screened 
populations as compared to controls—and whether the above two measures result in 
ultimately lower morbidity and mortality rates in the screened populations; greater 
proportions of high risk individuals attending the screenings; and increased frequencies of 
SSE’s [190]. In this respect, attempts at evaluating mass screenings have focused on 
evaluating the cancers found during the screenings, the access to the screenings, the risk 
profile of the screened participants, the educational effects of the screening programs, and 
the evaluation of the visual examination as a screening tool [190]. 
Regarding the cancers found in the screenings, studies from New York and 
Massachusetts have reported melanoma yields of 14 per 2239 and 9 per 2560, respectively 
[179, 296]. Also, evaluations of nationwide screenings in the United States have 
documented Breslow depths of less than 1.50 mm in almost 99% of the screen-detected 
melanomas [182]. In this respect, these screenings (conducted by the American Academy 
of Dermatology (AAD)) appear to detect early melanomas, with stage and thickness 
distributions comparing favorably with those of the SEER registry [325]. For instance, of 
individuals diagnosed with melanoma in the 1992-1993 AAD screening, 261 melanomas 
were histologically confirmed among 257 individuals, with all but four persons having 
localized disease [325]. When compared to the 1990 SEER population-based data, these 
figures were far more favorable, given that they had fewer advanced melanomas. However, 
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there is not only a possibility for self-selection bias [178, 325], but also an inability to predict 
improved mortalities [325]. 
Screening programs also have the additional benefit of providing access to medical 
care to such populations as the poor [62]. In the United States, the AAD screenings represent 
some groups’ sole opportunity for receiving skin cancer examinations [190]. Among those 
screened in the 1992 and 1993 campaigns, over 75% did not have a regular dermatologist, 
47% would not have seen their physician without the screen, and 9% had no health 
insurance. Also, 80% of the participants were attending their first screening, implicating 
screenings as many individuals’ first opportunity for expert skin examination [184, 325]. 
Regarding the risk profile of the participants, a Massachusetts study revealed a 
tendency toward self-selection among the participants, given that greater than 86% had at 
least one, and 78% had at least two melanoma risk factor(s) [184]. Also, data from 
Massachusetts and Rhode Island document that high risk individuals tend to appropriately 
self-select for screening, even though they have not been specifically targeted as a group 
[184,354], 
With respect to education, various measures ranging from prescreening publicity, 
education during the screenings, and postscreening efforts have been used, aimed at 
heightening public awareness of melanoma risk factors and warning signs, along with 
disseminating information on sun protection, excessive sun exposure, tanning parlors, guides 
to SSE, and the importance of early detection [190]. For instance, a Swedish study of 190 
individuals attending a melanoma screening clinic documented increased attention to nevi 
among the participants: those who were concerned about their nevi were reassured, while 
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those who were not so interested learned to pay more attention to their nevi [44], However, 
the long-term effects of such interventions still remain to be investigated [190]. 
The evaluation of the visual skin examination as a screening tool would entail 
determining its sensitivity, specificity, and positive predictive value. As mentioned earlier, 
the estimated sensitivity, specificity, and positive predictive value of the visual skin 
examination range from 73% to 99%, 92% to 99%, and 35% to 80%, respectively [20, 178, 
179, 191, 244, 327]. A study of university-based dermatologists with a special interest in 
melanoma documented estimates of 77%, 99%, and 80%, respectively, for the three 
parameters [191]. Meanwhile, the AAD screenings, more representative of the real world, 
have yielded a sensitivity of 97% and a positive predictive value of 35%-40% in 
Massachusetts, and a positive predictive value of 13%-24%, nationally [179, 180]. (The 
study design had not allowed the calculation of specificity values.) 
Also in an effort to evaluate the efficacy of the visual skin examination as a tool for 
detecting melanoma, a number of reports have documented the accuracy of dermatologists’ 
diagnosis of melanoma in the clinical setting: one study recorded an accuracy rate of 64% 
[191]; another study noted improvement in the clinical diagnosis of melanoma from 1955 
to 1982, with a sensitivity of 84.5% and a specificity of 72.4% in the most recent period 
(1974-1982) [146]; still another study revealed variations in clinical diagnosis with 
differences in tumor thickness—58% of lesions smaller than 2 mm, and 51% of those greater 
than 2 mm were correctly diagnosed [272]; and finally, one study reported significant inter¬ 
dermatologist differences in the assessment of skin images, when measures of diagnostic 
sensitivity, reproducibility, and reliability were evaluated [263]. 
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Public information campaigns have increasingly encouraged SSE as a means of 
screening for early melanoma lesions, with detailed directions for the proper examination, 
including the use of mirrors or “buddies” for otherwise difficult-to-see areas [117]. 
However, there are few, if any, quantitative data regarding the utility or efficacy of self¬ 
examinations as a screening technique [144, 190]. A prospective case-control study in 
Connecticut, hypothesizing that SSE reduces mortality through early detection of melanoma, 
will provide the first real information in this regard [30]. 
A study evaluating the SSE practices of 1344 Australians documented that 48% either 
self-screened or had their skin checked by another lay person [128]. In particular, men, those 
of lower occupational and educational status, the unemployed, the infirm, and those with 
only basic medical insurance were found to have poor self- and medical-screening practices. 
In the United Study, only one in five subjects with prior melanoma were found to practice 
SSE [185]. In another study, 61% of self-selected screenees reported performing SSE at 
least once during the previous year, whereas only 20% reported performing monthly SSE, 
and only a minority were knowledgeable about most of the recommended SSE steps [118]. 
Likewise, in a population of 874 dermatology patients, only 6% were found to follow all the 
recommendations for monthly SSEs, yearly professional examinations, and sun protection 
[206], which led the investigators to recommend a thorough skin examination for all new 
patients, and annual skin examinations for all return patients (given that most do not adopt 
the SSE recommendations). 
One study, evaluating general dermatology patients’ self-assessment of pigmentary 
risk factors for melanoma, recorded the number of freckles on the right forearm, the number 
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of palpable arm nevi, and the number of nevi greater than 5 mm in diameter on the entire 
body as determined by first the patients and then a dermatologist. Using the physician 
counts as the standard, the investigators reported a specificity of 83% to >95% for the three 
cutaneous markers, leading them to propose a tiered approach to screening: self-assessment 
of risk by SSE, followed by physician confirmation of that risk, and finally, more regular 
SSE and surveillance of those deemed to be high risk [148J. 
It is hoped that screening and close surveillance of high risk individuals would lead 
to earlier detection of malignant lesions, before the highly lethal stages are reached. Also, 
targeted screenings (of higher risk persons) should improve the predictive value of the exam 
[178]. Risk factors used to identify high risk individuals could include high nevus counts 
(or the presence of atypical nevi), red hair, freckling, and burning following repeated sun 
exposures [236, 340, 344], a changing nevus, and a family history of melanoma [292], 
As discussed earlier in the introduction, the NCI/UPenn prospective surveillance of 
multiple kindreds with the atypical nevus-melanoma syndrome led to the detection of 
significantly thinner lesions [237]. In this study, the average Breslow depth of the melanoma 
lesions were 0.52 mm for the 28 surveillance incident melanomas, 0.55 mm for the 64 non¬ 
surveillance incident melanomas, and 1.44 mm for the 48 index lesions (p <0.001). Also, 
the investigators have noted a significant decline in the proportion of tumors presenting in 
the vertical growth phase, from 80% to 41% [237]. A similar study in the Netherlands 
involving the surveillance of nine kindreds with the atypical nevus-melanoma syndrome 
revealed similar results [344]. The average Breslow depth of the melanoma lesions 
discovered prior to the study (n=19), at the initial examination for the study (n=l 1), and 
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detected during the routine follow-up in the course of the study (n=20) was 1.75 mm, 0.80 
mm, and 0.54 mm, respectively (p=0.001). These results have been reported by multiple 
other studies following individuals with atypical nevi [227, 295, 340], pinpointing the 
beneficial effects of surveillance and education in such high risk populations [237]. 
The increased incidence of melanoma among workers at the Lawrence Livermore 
National Laboratory—who were found to have a four-fold increased incidence of melanoma 
as compared to individuals from the surrounding community in the early 1980s—also 
prompted the prospective surveillance of this population. The intervention mounted for the 
early detection and treatment of melanoma adopted a multi-tiered strategy of educating 
employees, management, and local practitioners; promoting skin self-examinations and mole 
counting; and an on-site melanoma clinic for dermatologic examinations and treatment. 
Since this project’s onset, all the melanoma diagnoses have been thin (<0.76 mm) and in situ 
lesions, with an anticipated survival of 95%-100%, a median tumor thickness of zero (i.e., 
most lesions were in situ). Also, the median Breslow depth of melanomas in these workers 
declined significantly more rapidly as compared to that of the reference community 
population [7, 310]. 
Middle-aged and older men (50 years of age and above) might constitute another 
appropriate target group for education and early detection, given that they have the highest 
melanoma mortality rates—documented by data from the United States, Australia, and New 
Zealand [37, 66, 126, 152, 186, 346]—along with disproportionately lower levels of 
participation in mass screenings (which depend on patient self-referral). Lower 
socioeconomic groups may also constitute another appropriate target population, given that 
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a recent study reported that lower socioeconomic persons are more likely to die from their 
cancer than are individuals of higher socioeconomic status [190 (Geller et al., 1995)]. 
Review of International Screening and Education Efforts in Melanoma: 
Even though many of these efforts have been alluded to in previous sections, they 
will be discussed more formally in the following section. 
Australia: The Queensland Melanoma Project, which began in 1963, is the forefather 
of all population-wide screening efforts in melanoma [80, 317], The project initially began 
with a population-based retrospective survey of melanoma incidence and mortality in 
Queensland, spanning the years 1945-1963, which formally documented Queensland’s high 
melanoma incidence (the highest in the world), and lay the foundation for an ongoing 
statewide melanoma registry capable of providing up-to-date morbidity and mortality data. 
Then, the project launched an educational campaign targeting both professionals and the 
public through modifying medical school curricula, entering the school systems so as to 
reach children at an earlier, perhaps more impressionable age, and finally, utilizing all media 
forms, from publications and brochures, to television advertising and programing. Also, 
since 1985, these efforts have been complemented by screening caravans (known as “battle 
stations”) which examine individuals at such public locations as beaches and public squares, 
and refer those with suspicious lesions for further treatment [104]. In other instances, these 
large community-based public health campaigns have been supplemented by industry-based 
programs (initiated by the industries themselves, targeting their workers’ specific needs), 
with favorable preliminary results [39]. 
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In terms of televised programing, for instance, “Good-bye Sunshine” was the most 
notable one, consisting of three televised “episodes” about melanoma spaced over a 2-year 
period, featuring the story of a 26 year old man diagnosed with invasive melanoma [334]. 
The episodes chronicled first, the impact of the melanoma—metastatic at the time of 
diagnosis—on the man and his girlfriend, his crusade against melanoma on beaches and other 
public settings, and finally, his death, interspersing emotional and tearful scenes with 
information on the signs and symptoms of melanoma and the importance of prevention and 
early detection. The program was shown to affect not only the viewers’ knowledge levels, 
but also their sun-related preventive practices. Also, the program improved viewers’ skin 
awareness and skin self-examination behavior, in that more than half reported examining 
their skin for “suspicious” spots as depicted in the program. In the meantime, there was a 
143% and a 100% increase in the number of diagnosed melanomas in the two consecutive 
years following this program’s broadcast. Also, the mean Breslow depth of the melanoma 
lesions decreased significantly from 1.59 mm to 0.91 mm, while the proportion of tumors 
<0.75 mm in Breslow depth increased significantly, from 50% to 74% [334], 
Another component of the campaigns consisted of a three-year SunSmart melanoma 
prevention campaign, aimed at promoting melanoma prevention by reducing sun-exposure, 
and more specifically, sunburns [153, 154], The behavior changes induced by the campaign 
significantly reduced the frequency of sunburns over the period. There were also significant 
shifts in public attitudes: there was a markedly changed public perception of susceptibility 
to skin cancer, with significantly fewer individuals denying their risk of developing skin 
cancer; there was a markedly changed attitude towards suntans, with an increase from 39% 
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to 51 % of individuals not desiring any degree of suntan. Also, the campaign significantly 
increased the use of protective measures, such as wearing hats and applying sunscreens [153, 
154], 
These educational efforts have remained continuous and ongoing in Australia, given 
that decreases in these efforts were associated with reductions in melanoma awareness [144]. 
These activities have had favorable results: the proportion of in situ, stage I melanomas 
(tumor cells confined to the epidermis) rose from 9% in the early years of the project (1963- 
1969) to 26% in 1977; there was a 25% increase in the proportion of stage II melanomas 
(tumor cells invading the papillary dermis); and the five-year mortality decreased from 41% 
to 26% [243]. During 1963-1969 period, nearly three quarters of males and two thirds of 
females had primary tumors of Clark levels III, IV, or V (tumor cells expanding the papillary 
dermis, invading the reticular dermis, and invading subcutaneous fat, respectively), whereas 
by 1977 only half of males and just under half of females had such tumors [243]. Also, even 
though melanoma incidences continued to rise in the same period (from 16 per 105 in 1963 
to 34 per 105 in 1979 [317]), the melanoma mortality rates stabilized [243]. In fact, due to 
these interventions, despite having the highest melanoma incidence rates, Australia has 
higher survival rates than North America and Europe [11, 151]. 
New Zealand: The New Zealand Cancer Society has sponsored “skin check” days, 
attended by more than 12,000 individuals in the 1988-1989 period [104, 190]. The screening 
efforts have been complemented by intensive advertising through both television and printed 
material. Moreover, in the Wellington region, the 1985-1992 public education campaigns 
led to significant increases in not only the total number of treated melanomas, but also the 
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number and proportion of thin (<0.75 mm in Breslow depth) invasive melanomas, from 30% 
in 1985 to 70% in 1992 [337]. 
Italy: A public education campaign was launched in the province of Trentino, Italy, 
targeting both professional and non-professional audiences, while also establishing free 
clinics for the expeditious referral of patients with suspicious lesions [70]. The investigators 
compared the standardized mortality rates for Trentino with those of three neighboring 
regions where no campaigns were carried out, over time. The campaign resulted in a four¬ 
fold increase in patient consultations, tripling of excisions, and doubling of melanoma 
diagnoses, and an eight-fold increase in the proportion of lesions <0.76 mm in Breslow 
depth, from 2.5% to 21% [70]. Also, the campaign resulted in a decline in melanoma 
mortality rates in women, and a mild increase in melanoma mortality rates in men in 
Trentino, in comparison with the mortality rates in the surrounding regions, which continued 
to rise at the high pre-campaign rates [70]. 
United Kingdom: Perhaps the most thorough (in both design and execution) of 
contemporary melanoma screening programs was conducted in the west of Scotland. The 
discovery that nearly one third of Scottish patients were presenting with melanoma lesions 
>3.5 mm in Breslow depth (with an associated five-year survival of 38%) prompted a survey 
to assess the reason underlying this delay in diagnosis. The survey attributed the delay in 
diagnosis to patients’ lack of knowledge about melanoma characterisitics and failure to 
appreciate the significance of changing pigmented lesions, and not to shortcomings in the 
health care system [79]. This led to the design of a public education campaign to inform the 
public about the features of early melanoma, and to encourage them to seek treatment [80]. 
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Moreover, the six-month period preceding the public phase of the campaign was set aside 
for professional education and update, accomplished through the mailing of a detailed 
booklet on melanoma, with color illustrations of early lesions, along with problem-solving 
case histories and an educational video. These were complemented by a series of educational 
meetings for both physicians and nurses. Also, a weekly pigmented lesion clinic was 
established for the immediate care of referred patients. The public education phase of the 
campaign involved posters, brochures, and a press release for the local and national press, 
radio, and television [80]. 
The campaign resulted in a 278% increase in the number of referrals to the specialty 
pigmented lesion clinic; an increase in the mean number of melanomas diagnosed per month, 
from 12 to 21; a 23% rise in the total number of melanomas diagnosed; and a significant 
(16%) rise in the proportion of thin melanomas (<1.5 mm in Breslow depth). By three years, 
the campaign had resulted in a significant decline in the proportion of thick tumors (>3.5 
mm in Breslow depth) among the females only, which translated into a decreasing mortality 
rate in this group—the first direct evidence of such an effect ever noted in a melanoma 
screening program [225]. 
A few years after the Scottish experience, public education campaigns were launched 
in seven additional regions throughout the United Kingdom [92]. In the region served by the 
King’s College Hospital (described earlier), the evaluation entailed reviewing all melanoma 
specimens from 1970 to 1987. This study traced the greatest decrease in tumor thickness to 
the late 1970's, from a median Breslow depth of 4 mm to 1.5 mm, along with an increase in 
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the proportion of thin lesions (<1.5 mm) and a decrease in both the proportion and absolute 
number of thick lesions (>3.5 mm). This pattern altered little during the campaign years 
[360], 
In Leicestershire, there were three consecutive, annual public education campaigns, 
resulting in the diagnosis of significantly higher numbers of melanoma immediately after the 
first campaign, lower numbers following the second and third years, and again, increased 
numbers in the fourth and fifth (non-campaign) years. Also, the campaigns led to a 
significant rise in the proportion of thin (<1.50 mm) lesions, and a significant decline in the 
proportion and absolute number of the thickest (>3.5 mm) lesions [150]. It was reasoned 
that the “early” diagnosis of melanomas immediately following the first campaign led to an 
artifactual lowering of melanoma diagnoses in the second and third campaign years—when 
the “early” melanomas would have been detected otherwise. The rise in the number of 
melanoma diagnoses in the fourth and fifth (non-campaign) years was attributed to the 
“wearing off’ of the impacts from the first campaign. The investigators concluded that, in 
low melanoma incidence regions like the U.K., pulsatile publicity may be more effective 
than annual or continuous ones [150], 
Finally, given that childhood sunburns constitute a significant risk factor for 
melanoma, a health education program was developed for secondary schools, modeled after 
a similar program (with encouraging results) in Australia. Seven schools in various regions 
of England were recruited for the study, to which educational material on melanoma in the 
form of pamphlets, workbooks, and a video, were distributed [168]. The effects of the video 
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on students’ knowledge, attitudes, and behavior were assessed through pre- and post¬ 
questionnaires. Despite significant differences in both knowledge and attitude between the 
intervention groups and the controls, there were no significant differences in behavior 
between the groups, except in relation to the use of sunscreen. Also, more children reported 
using sunscreen and wearing a hat if they traveled abroad (revealing a subjective association 
of sunburns with sunlight abroad, as opposed to local sunlight). Meanwhile, with respect to 
attitudes, those who either covered up in the sun, wore sunscreen, or sat in the shade had 
significantly better attitudes than those who did not behave in this way [168], 
The United States: In response to the growing incidence and mortality of melanoma 
and the continued ignorance of the public about melanoma, the American Academy of 
Dermatology (AAD) initiated the National Melanoma/Skin Cancer Prevention Program in 
the spring of 1985 [239, 325], enlisting the volunteer services of AAD dermatologists and 
American Cancer Society volunteers to examine an essentially self-selected population. 
Concurrently, each screening was preceded by national and local media (newspapers, radio, 
and television) help, augmenting these efforts by publicizing the screening times, 
encouraging attendance [190], and disseminating information on melanoma risk factors and 
warning signs, the importance of sun protection and early detection—and even performing 
skin self-examinations [239]. Other educational materials included posters, a 15-minute skin 
cancer slide/script set designed for presentation to community groups and organizations, an 




Thus, between 1985 to 1993, the AAD provided free skin screening to more than 
600,000 Americans [325]. The screening participants first completed a standardized form 
on risk factors, changing moles, and family and personal history of skin cancer and 
melanoma, after which they were examined by the AAD physicians. Suspicious lesions were 
referred to the individual’s primary physician for diagnosis and treatment. Of the 559 
persons diagnosed with skin cancer from 1989 to 1991, 176 were melanomas: 173 (98%) 
were stage I [185b]; 104 (59%) were less than 1.5 mm in Breslow depth (associated with an 
86% five-year survival) [10, 46], 
Meanwhile, there have also been other public education and screening campaigns 
independent of those of the AAD. For instance, in New Mexico, following the establishment 
of a melanoma registry in 1980 for more consistent diagnosis and pathologic staging (e.g., 
in 1981, only 47% of the melanoma diagnoses had a documented Breslow depth), the 
proportion of Clark level I and II lesions increased from 38% in 1981 to 61% in 1985, and 
the proportion of melanomas with Breslow depth less than 1 mm increased from 46% in 
1981 to 66% in 1985. This was attributed to the variety of educational programs instituted 
for both the public and various professionals, as well as the Registry’s regular news letters 
to physicians and sporadic press releases via the public media [32], 
The Arizona Cancer Center initiated the Arizona Sun Awareness Project after a 1979 
report identified melanoma as a serious public health hazard in the region [312]. Over the 
years, this project has grown into a comprehensive, multifaceted community health 
promotion vehicle, using several original educational media (including a skin cancer 
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prevention videotape, a sun awareness brochure, a health fair display, and a puppet show 
accompanied by an activity booklet for children in grades kindergarten through 6) [217]. 
The evolution of the Arizona Sun Awareness Project has also culminated in two 
developmentally appropriate, age-based curricula aimed at teaching children about the 
benefits and dangers of the sun (given that excessive sun-exposure in early childhood has 
been linked to melanoma development later in adulthood) [217]. Of these programs, one. 
Sunny Days, Healthy Ways targeted elementary school children, while the other, Be Sun Safe, 
was aimed at pre-school children. The choice of the target populations was influenced by 
studies documenting that (1) 29-70% of adolescents never/do not regularly use sunscreen, 
despite an awareness of the rationale for its use [15b, 61, 147b, 258b]; and (2) even 
elementary school children who have received formal skin cancer prevention education, with 
clearly improved knowledge and attitude toward sun protection, have problems incorporating 
preventive behaviors into their lifestyles [48, 275]. Such data seemed to suggest the need 
for targeting children at younger, more impressionable ages, or initiating student-parent 
programs, to increase the likelihood of behavior modification [67, 218]. 
The Sunny Days, Healthy Ways curriculum, entailing a multi-disciplinary and 
comprehensive approach to education about the sun, skin cancer, and prevention strategies, 
while also attempting to instill a sense of control and responsibility for disease prevention, 
detection, and control, consisted of a series of five hour-long lessons in an interactive/active 
format for students in grades 4 through 6. Beyond the in-class lessons and activities, the 
project had take-home materials, a glossary, a review, and a student-parent newsletter [217], 
The curriculum resulted in increased knowledge at both the immediate post-intervention 
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period, and eight weeks later. The lessons also reduced favorable attitudes toward tanning, 
while improving attitudes toward sunscreen use. Behavioral modifications were less 
consistent, with lower reports of suntanning, more frequent use of sunscreen among fourth 
graders, and increased use of protective clothing among firth and sixth graders [48]. Later, 
the Sunny Days, Healthy Ways messages were delivered to a similar population of students 
in a condensed, day-long curriculum format and a sun safety health fair format. The study 
results revealed the greatest improvement in knowledge among fourth graders in both 
formats. Also, not surprisingly, the day-long curriculum format was more efficacious than 
the health fair one, while the original (five-lesson) format was even more efficacious than 
these modified versions, suggesting that attitude and behavior modification require more 
intensive, continuous interventions [48, 217]. 
After the Sunny Days, Healthy Ways program, the investigators became curious to 
learn the youngest age at which sun safety education would have an effect [217]; this 
question led to the development of the Be Sun Safe project for pre-schoolers and their 
parents. This project emphasized developmentally appropriate, sun safety concepts such as 
“find shade”, “cover up”, and “ask for sun-safe things” (in three 45- to 50-minute units), 
while also trying to promote positive health habits such as self-protection from sunburns and 
taking care of one’s body. It avoided the concept of “skin cancer”, which would have been 
poorly understood and frightening in this age group. Thus, the curriculum included a section 
for teacher information, classroom activities (from engaging in theme-specific games, songs, 
and story-telling, a puppet show, etc.), take-home activities to do with care givers, a glossary, 
and a reference list of learning resources. The curriculum resulted in significantly increased 
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knowledge levels, with attitudes centering on not getting sunburned. However, there was no 
behavioral change, which had been expected by the investigators, given the target 
population’s age [218], 
The Under Cover Skin Cancer Prevention Project was a community-based program 
utilizing media partners (newspapers, radio, and television) in three Texas cities, to 
disseminate UV radiation readings (in the form of the minimal erythema dose) four times per 
day, along with education and behavioral change messages [41, 125], This program 
documented significant changes in the behavioral practice of sun avoidance among the study 
sample over four months. However, it also drew attention to the need for constructs centered 
around peer pressure and social norms, which were documented to be key determinants of 
voluntary sun exposure [41]. 
Canada: The Canadian Dermatology Association (CDA) has been supervising the 
Sun Awareness Program, aimed at increasing public awareness of the dangers of UV 
radiation, as well as providing information on prevention and early detection [299]. This 
program entails an annual national press campaign (involving national, provincial, and 
community newspapers, periodicals, and French and English radio public service 
announcements), the distribution of educational materials (posters and brochures, including 
information to all mothers on the importance of sun-protection in newborns and children, as 
well as general information on protection from excessive sunlight and artificial sources of 
UV light), the organization of screening stations throughout the country during the “Sun 
Awareness Week”, and finally, providing daily information on UV intensity through 
Environment Canada’s UV index program. 
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To maintain public and media interest, the CDA has focused on an annual theme each 
year; past themes have included the importance of early detection, the importance of sun- 
protection during childhood, and sun protection by way of hats and proper clothing. Also, 
more recently (since 1992), the CDA has been launching a primary school education 
program targeting grades 1 through 3 (i.e., children 6 to 8 years of age). This program, 
entitled “Living with Sunshine”, has enlisted the help of elementary school teachers. First 
piloted in five provinces, it is now an approved curriculum resource throughout Canada. 
The CDA modeled its screening campaigns after the Australian beach “battle 
stations”, starting in 1991 as a pilot study in Vancouver (with screenings on seven different 
weekends) and later expanded in scope, though limited to a single weekend. To monitor the 
screenings, questionnaire surveys were distributed to all participants; the surveys revealed 
the presence of at least one melanoma risk factor in 67% of the participants [299]. Overall, 
however, there is still a need for more formal and systematic evaluation of these intervention 
efforts. 
The Netherlands: In the Netherlands, there have been public education campaigns, 
along with two screening programs [199, 273]. In one study, 2564 individuals were screened 
for skin cancer, leading to the discovery of 10 melanoma and 43 non-melanoma skin cancers 
[273]. In the second study, 3069 individuals were screened at four beach-side resorts, over 
4 consecutive Saturdays, using a mobile trailer, leading to the diagnosis of 6 melanomas (all 
less than 1 mm in Breslow depth) [359], 
Switzerland: The evaluation of the Swiss campaign, consisting of a national 
information program, revealed a doubling of the number of melanoma diagnoses in the two 
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months following the launch of the campaign, along with a shift in the case distribution 
toward younger ages (younger than 60 years of age) [49], 
Austria: The first Austrian melanoma educational campaign was conducted in 1988. 
It involved not only professional education—through providing illustrated folders and 
publications on the clinical appearance and nature of pigmented lesions to all Austrian 
surgeons, dermatologists, and general practitioners—but also public education through the 
media—including articles and interviews in newspapers, broadcast television notices, and 
posters at physicians’ offices, schools, and other public places [261]. The campaign resulted 
in a significant increase in the number of melanomas diagnosed, as well a significant decline 
in the median Breslow depth of the lesions (from 1.4 mm in the pre-campaign years, to 1.1 
mm year in the year of the campaign, and 0.95 mm in the first post-campaign year). Also, 
there was a significant rise in the proportion of thin tumors (<0.75 mm) from the pre¬ 
campaign to the post-campaign years. 
Other Methods of Melanoma Screening: 
The skin cancer screening programs discussed above, exemplified by the American 
Academy of Dermatology, for instance, represent but one method of screening—i.e., episodic 
screening performed by dermatologists on self-selected populations [178]. Other methods 
of screening would also need to be instituted to more effectively control the escalating 
melanoma incidence and mortality rates. 
Screening as Part of a Routine Medical Visit: Many have called for the integration 
of a thorough skin examination into the routine physical examinations provided by primary 
health practitioners [42, 75], These serve as excellent opportunities for the early detection 
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of possible malignant lesions, in as much as approximately 85% of the U.S. population visits 
a physician every 2 years, and routine physical examinations are among the 10 most common 
reasons for seeing a physician [114, 157]. Also, about 7% of all outpatient visits are 
dermatologic in nature, while dermatologists see only a third of these disorders [322], In one 
study, approximately half (53%) of the melanomas were self-detected, 26% were detected 
by medical providers, and 17% were detected by relatives; and of the subpopulation of 
melanomas discovered by a physician, only 12% were discovered by a dermatologist [185]. 
Experts differ in their stance regarding routine skin examinations (for early melanoma 
detection) in the context of medical visits. While some sources recommend routine skin 
examination of all adults, though more frequently for older adults, others leave it optional. 
Some recommend the training of all types of physicians, as well as nurses, paramedical 
personnel, medical students, and even, chiropractors and physical therapists, in the diagnosis 
of melanoma, while others fear poor sensitivity and specificity in the hands of non¬ 
dermatologists [51, 274, 347]. 
Meanwhile, from a practical standpoint, such a venture would face many obstacles. 
First, data have documented that an average visit to a family physician or general practitioner 
lasts 14 minutes, while the average visit to a general internist lasts 17 minutes [341], In view 
of the growing demand on primary care services and the continued inadequate supply of 
primary care providers, an increase in the average length of time per visit, (to include a 
complete skin examination) would seem unlikely [357], Second, many patients have 
multiple medical problems which would contribute to the lack of time for complete skin 
examinations [357]. Indeed, the need to review multiple active problems would detract 
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attention from such preventive measures as skin examination for skin cancer [24], Third, the 
lack of reimbursement for preventive services represents a major obstacle to the practice of 
preventive skin examinations [357]. Finally, primary practitioners’ lack of expertise in 
melanoma diagnosis and management might contribute to their unwillingness to provide 
complete skin examinations [357]. 
Self-Screening though Regular Skin Self-Examinations (SSE'): There is growing 
publicity about SSEs (akin to the breast [210] and testicular self-examinations) for the early 
detection of melanoma. By performing SSEs, individuals assume a more active role in their 
health care, taking partial responsibility for identifying melanoma lesions at a potentially 
more curable stage. The proper method of performing SSEs has been detailed [116], and the 
AAD and the American Cancer Society provide additional educational pamphlets for patient 
information. 
As cited earlier, in one study, more than half (53%) the melanomas were self- 
detected, and there was a significant association between regular SSEs and more frequent 
self-discovery of the melanomas (p=0.02) [185]. Such evidence implicates regular SSE for 
potential signs of melanoma as a particularly efficacious means of reducing melanoma 
mortality rates [30]. 
Others: Screening for melanoma could be organized through the workplace, for a 
more inclusive approach, or be targeted at high risk populations, such as those with the 
atypical nevus-melanoma syndrome. Examples of both have been described earlier, as with 
the Lawrence Livermore Laboratory and the NCI/UPenn prospective surveillance studies. 
Therefore, they shall not be discussed again. Elowever, some experts [172] have indicated 
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their skepticism of the “target” approach to melanoma surveillance, believing the identified 
risks to be too small to be useful for the selection of an appropriate subpopulation, while also 
considering the proportion of cases in the low-risk populations to be substantial. Instead, 
they have called for unselective screening (while taking into account known risk factors), 
followed by grouping into high- and low-risk categories, which would later allow a risk- 
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Table 3 - Demographic and Phenotypic Characteristics 
GROUPS MELANOMA NEVUS CONTROL P-VALUE 
CLINICAL CHARACTERISTICS 
SEX FEMALE 20 (61%) 25 (76%) 14 (70%) 
MALE 13 (39%) 8 (24%) 6 (30%) - 
AGE 18-35 6 (18%) 15 (45%) 3 (15%) 
36-50 13 (39%) 13(39%) 4 (20%) 0.001 
51-85 14 (42%) 5(15%) 13 (65%) 
AGE, MEAN 47 (A) 38 (B) 54 (A) 
OCCUPATIONAL 6(A) 7(A) 6(A) 
SCORE, MEAN 
MAJOR/INTRMED PROFESS'L 6 (18%) 9 (27%) 4 (21%) 
MINOR/SEMI- PROFESS'L 18 (55%) 18 (55%) 10 (53%) 
CLRK/SALES/SKILLED + SEMI- 5 (15%) 1 (3%) 2 (10%) - 
UNSKILLED/MENIAL SERVICE 1 (3%) 0 1 (5%) 
UNKNOWN 3 (9%) 5 (15%) 2 (10%) 
HAIR BLOND/RED 12 (36%) 8 (24%) 4 (20%) 
L. BROWN 11 (33%) 4(12%) 5 (25%) - 
BROWN/BLACK 10(30%) 21 (64%) 11 (55%) 
BLUE/GREEN 21 (64%) 15 (45%) 8 (40%) 
EYES HAZEL/GREY 6 (18%) 5(15%) 3 (15%) 
L./D. BROWN 6 (18%) 13(39%) 8 (40%) - 
DK 0 0 1 (5%) 
SKIN TYPE** BLISTER'G SUNBURN 3 (9%) 2 (6%) 2 (10%) 
BURNABILITY PAINFUL SUNBURN 15 (45%) 13 (39%) 7 (35%) 
MILD BURN W/ LITTLE TAN 15 (45%) 17 (52%) 7 (35%) - 
TAN W/O SUNBURN 0 1 (3%) 2 (10%) 
DK 0 0 2 (10%) 
SKIN TYPE** FRECKLES/NO TAN 3 (9%) 3 (9%) 2 (10%) 
INABILITY TO TAN MILD TAN W/ H/O PEELING 7 (21%) 5 (15%) 3 (15%) 
MODERATE TAN 21 (64%) 19 (58%) 9 (45%) - 
DEEP, BROWN TAN 2 (6%) 5 (15%) 4 (21%) 
DK 0 1 (3%) 2 (10%) 
Based on a patient's own subjective assessment of his/her acute and chronic reaction to sunlight. 

Table 4 - Malignant Melanoma Risk Factors of Subjects in the Study. 
GROUPS MELANOMA NEVUS CONTROL P-VALUE 
MM RISK FACTORS 
OBJ # NEVI 0-33 20 (61%) 12 (36%) 19 (100%)1 
34-66 10 (30%) 12 (36%) 0 0.001 
67-100 & >100 3 (9%) 9 (27%) 0 
SUBJ # NEVI 0-33 19 (58%) 13(39%) 17 (85%) 
34-66 7 (21%) 4 (12%) 1 (2%) 0.001 
67-100 & >100 7 (21%) 16(48%) 2 (10%) 
% Correct 17 (52%) 18(55%) 17 (85%) 0 051 
MORE NEVI? YES 12 (36%) 23 (70%) 4 (20%) 
NO 16 (48%) 8 (24%) 14 (70%) - 
DK 5 (15%) 2 (6%) 2 (10%) 
% Correct 24 (73%) 27 (82%) 14 (70%) - 
PHx A. NEVI YES 22 (67%) 33 (100%) 1 (5%)2 
NO 11 (33%) - 19 (95%) 0.001 
PHx NMSCa YES 5 (15%) 5 (15%) 4 (20%) 
NO 28 (85%) 27 (82%) 15 (75%) - 
DK - 2 (6%) 1 (5%) 
FHx MM YES 9 (27%) 14 (42%) 3 (15%) 
BY SELF-REPORT 3 (33%) 4 (29%) 3 (100%) 
DOCUMENTED 6 (67%) 10(71%) - - 
NO 22 (67%) 15 (45%) 14 (70%) 
DK 2 (6%) 4 (12%) 3 (15%) 
FHx NMSCa YES 16 (48%) 11 (33%) 4 (20%) 
NO 11 (33%) 19 (58%) 10 (50%) - 
DK 6 (18%) 3 (9%) 6 (30%) 
1- One subject lacks an objective nevus count as a result of being recruited through a dermatologic surgery UGDC. 
2- A control, followed in the university general dermatology clinic for the diagnoses of lupus and psoriasis, 
incidentally documented to have an AN 

Table 5 - Analysis of Baseline & Follow-up Knowledge of Specific Melanoma Facts By Group. 
GROUPS MELANOMA 
BEFORE 
NEVUS CONTROL P-VAL MELANOMA 
AFTER 
NEVUS CONTROL P-VAL 
SIGNIFICANT CHANGE? 
MELNM NEVUS CONTRL 
SIGNIFICANT CHANGE? 
MELNM NEVUS CONTRL P-VALUE 
KNOWLEDGE QUESTIONS MEANS MEANS MEANS INCREASE INCREASE INCREASE 
CHNG SHAP/COLR/SIZE 33 (100%) 33(100%) 18 (90%) 0.034 32 (97%) 31 (94%) 19(95%) - / / / 0 0 1 (5%) - 
ABNL SHAPE 33(100%) 32 (97%) 13 (65%) 0.001 32 (97%) 32 (97%) 16(80%) 0.033 / / / 0 1 (3%) 5 (25%) 0.007 
DARKA/AR COLOR 32 (97%) 30 (91%) 13(65%) 0.018 33 (100%) 31 (94%) 17(85%) - / / / 1 (3%) 3 (9%) 5 (25%) - 
INCR'D THICKNESS 27 (82%) 31 (94%) 14(70%) 0.021 27 (82%) 27 (82%) 17 (85%) - / / / 5(15%) 1 (3%) 5 (25%) 0.018 
NON-HEALING LESION 24 (73%) 30 (91%) 17 (85%) - 23 (70%) 31 (94%) 19(95%) - / / / 3 (9%) 1 (3%) 3 (15%) - 
BLEEDING 24 (73%) 29 (88%) 9 (45%) 0.001 23 (70%) 31 (94%) 14 (70%) 0.021 B B A 0 2 (6%) 6 (30%) 0.013 
TENDERNESS 23 (70%) 23 (70%) 9 (45%) - 19 (58%) 24 (73%) 15(75%) - B B A 0 5(15%) 7 (35%) - 
ITCHING 18(55%) 25 (76%) 4 (20%) 0.001 19 (58%) 27(82%) 7 (35%) 0.001 / / / 4(12%) 4(12%) 7 (35%) 0.053 
LARGE 13 (39%) 23 (70%) 3 (15%) 0.001 15 (45%) 22 (67%) 8 (40%) 0.045 B C A 5 (15%) 1 (3%) 5 (25%) 0.018 
SURVEY BACK NEVI 18 (55%) 15 (45%) 6 (30%) - 25 (76%) 19(58%) 16(80%) - B C A 10(30%) 9 (27%) 11 (55%) 0.056 
CHILDHOOD SUNBURNS 32 (97%) 32 (97%) 18 (90%) - 32 (97%) 33(100%) 19 (95%) - / / / 1 (3%) 1 (3%) 2 (10%) - 
CURE BY EARLY DISC / 33 (100%) 29 (88%) 18 (90%) - 33 (100%) 31 (94%) 17 (85%) - / / / 0 2 (6%) 1 (5%) - 
FHx MM 30 (91%) 27 (82%) 16(80%) - 32 (97%) 30 (91%) 17 (85%) - / / / 3 (9%) 3 (9%) 3 (15%) - 
ITCHY MOLE 22 (67%) 29 (88%) 15 (75%) - 23 (70%) 29 (88%) 14(70%) - / / / 4(12%) 2 (6%) 3 (15%) - 
?MM=BLACK & HAIRY? 29 (88%) 29 (88%) 10 (50%) 0.003 31 (94%) 27 (82%) 12 (60%) - / / / 2 (6%) 1 (3%) 5 (25%) 0.013 
DISAPP'ING MOLE 5(15%) 14 (42%) 1 (5%) 0.001 9 (27%) 16(48%) 3 (15%) 0.009 / / / 6(18%) 5 (15%) 3 (15%) - 
CHANGING MOLE 33 (100%) 32 (97%) 20 (100%) - 33(100%) 32 (97%) 20 (100%) - / / / 0 0 0 - 
BLUE EYES/RED HAIR 33 (100%) 32 (97%) 19 (95%) - 33 (100%) 32 (97%) 20 (100%) - / / / 0 0 1 (5%) - 
FHx MM x2 33(100%) 32 (97%) 19 (95%) - 33(100%) 31 (94%) 19(95%) - / / / 0 0 0 - 
BURNS, NEVER TANS 32 (97%) 33 (100%) 18 (90%) - 33(100%) 33(100%) 20 (100%) - / / / 1 (3%) 0 2 (10%) - 
F/PHx & MANY MOLES 32 (97%) 32 (97%) 19 (95%) - 33(100%) 33(100%) 20 (100%) - / / / 1 (3%) 1 (3%) 1 (5%) - 
PHx MM 31 (94%) 33(100%) 19 (95%) - 31 (94%) 33(100%) 20 (100%) - / / / 1 (3%) 1 (3%) 1 (5%) - 
NO MOLES/DARK HAIR 33 (100%) 31 (94%) 15 (75%) 0.039 33(100%) 33(100%) 20 (100%) - B B A 0 2 (6%) 5 (25%) 0.039 
LARGE/ODD MOLES 31 (94%) 32 (97%) 17 (85%) - 31 (94%) 33(100%) 18 (90%) - / / / 1 (3%) 1 (3%) 3(15%) - 
>50 NEVI 30 (91%) 31 (94%) 19(95%) - 30(91%) 32 (97%) 18 (90%) - / / / 2 (6%) 1 (3%) 0 - 
BLACK SKIN 27 (82%) 27 (82%) 16(80%) - 33(100%) 28 (85%) 16(80%) - / / / 3 (9%) 2 (6%) 1 (5%) " 
' 
Table 6 - Analysis of Baseline & Follow-up Knowledge of Specific Melanoma Facts By Clinic. 
GROUPS PLC 
BEFORE 
CONTROL P-VALUE PLC 
AFTER 
CONTROL P-VALUE 
SIGNT CHANGE? SIGNT CHANGE? 
PLC CONTRL PLC CONTRL P-VAL 
KNOWLEDGE QUESTIONS MEANS MEANS INCREASE INCREASE 
CHNG SHAP/COLR/SIZE 66 (100%) 18 (90%) 0.01 63 (95%) 19(95%) - / / 0 1 (5%) - 
ABNL SHAPE 65 (98%) 13 (65%) 0.001 64 (97%) 16(80%) 0.009 / / 1 (2%) 5 (25%) 0.001 
DARKA/AR COLOR 62 (94%) 13 (65%) 0.001 64 (97%) 17 (85%) 0.046 / / 4 (6%) 5 (25%) 0.016 
INCR'D THICKNESS 58 (88%) 14(70%) - 54 (82%) 17(85%) - / / 6 (9%) 5 (25%) - 
NON-HEALING LESION 54 (82%) 17 (85%) - 54 (82%) 19 (95%) - / / 4 (6%) 3 (15%) - 
BLEEDING 53 (80%) 9 (45%) 0.002 54 (82%) 14 (70%) - B A 2 (3%) 6 (30%) 0.001 
TENDERNESS 46 (70%) 9 (45%) 0.045 43 (65%) 15 (75%) - B A 5 (8%) 7 (35%) 0.002 
ITCHING 43 (65%) 4 (20%) 0.001 46 (70%) 7 (35%) 0.005 / / 8 (12%) 7 (35%) 0.019 
LARGE 36 (55%) 3 (15%) 0.002 37 (56%) 8 (40%) - B A 6 (9%) 5 (25%) - 
SURVEY BACK NEVI 33 (50%) 6 (30%) - 44 (67%) 16 (80%) - B A 19(29%) 11 (55%) 0.032 
CHILDHOOD SUNBURNS 64 (97%) 18 (90%) - 65 (98%) 19(95%) - / / 2 (3%) 2 (10%) - 
CURE BY EARLY DISC 62 (94%) 18 (90%) - 64 (97%) 17 (85%) 0.046 / / 2 (3%) 1 (5%) - 
FHx MM 57 (86%) 16(80%) - 62 (94%) 17 (85%) - / / 6 (9%) 3 (15%) - 
ITCHY MOLE 51 (77%) 15 (75%) - 52 (79%) 14 (70%) - / / 6 (9%) 3 (15%) - 
?MM=BLACK & HAIRY? 58 (88%) 10(50%) 0.001 58 (88%) 12(60%) 0.005 / / 3 (5%) 5 (25%) 0.006 
DISAPP'ING MOLE 19(29%) 1 (5%) 0.028 25 (38%) 3 (15%) - / / 11 (17%) 3(15%) - 
CHANGING MOLE 65 (98%) 20(100%) - 65 (98%) 20(100%) - / / 0 0 - 
BLUE EYES/RED HAIR 65 (98%) 19(95%) - 65 (98%) 20 (100%) - / / 0 1 (5%) - 
FHx MM x2 65 (98%) 19 (95%) - 64 (97%) 19 (95%) - / / 0 0 - 
BURNS, NEVER TANS 65 (98%) 18 (90%) - 66 (100%) 20(100%) - / / 1 (2%) 2 (10%) - 
F/PHx & MANY MOLES 64 (97%) 19 (95%) - 66 (100%) 20(100%) - / / 2 (3%) 1 (5%) - 
PHx MM 64 (97%) 19(95%) - 64 (97%) 20(100%) - / / 1 (2%) 1 (5%) - 
NO MOLES/DARK HAIR 64 (97%) 15(75%) 0.002 66 (100%) 20(100%) - B A 2 (3%) 5 (25%) 0.002 
LARGE/ODD MOLES 63 (95%) 17 (85%) - 64 (97%) 18 (90%) - / / 2 (3%) 3(15%) 0.046 
>50 NEVI 61 (92%) 19(95%) - 62 (94%) 18 (90%) - / / 3 (5%) 0 - 
BLACK SKIN 54 (82%) 16(80%) - 55 (83%) 16 (80%) - / / 5 (8%) 1 (5%) 

Table 7 - Group Knowledge Scores Stratified into Percentiles. 
MELANOMA NEVUS CONTROL PLC 
SCORE1 0% 0 0 1 (5%) 0 
1% -37% 1 (3%) 0 2 (10%) 1 (2%) 
38% - 74% 15(45%) 13 (39%) 16 (80%) 28 (42%) 
P-value 
75% -100% 17 (52%) 20 (61%) 
0.001 
1 (5%) 37 (56%) 
0.001 
SCORE1A 0% 0 0 0 0 
1 % - 37% 1 (3%) 2 (6%) 1 (5%) 3 (5%) 
38% - 74% 18 (55%) 11 (33%) 14 (70%) 29 (44%) 
P-value 
75% - 100% 14 (42%) 20 (61%) 
0.036 
5 (25%) 34 (52%) 
SCORE2 0% 0 0 0 0 
1 % - 37% 3 (9%) 2 (6%) 4 (20%) 5 (8%) 
38% - 74% 16 (48%) 16 (48%) 12 (60%) 32 (48%) 
P-value 
75% - 100% 14 (42%) 15 (45%) 
0.042 
4 (20%) 29 (44%) 
0.027 
SCORE2A 0% 0 0 0 0 
1% -37% 0 1 (3%) 3 (15%) 1 (2%) 
38% - 74% 14 (42%) 12 (36%) 11 (55%) 26 (39%) 
P-value 
75% - 100% 19 (58%) 20 (61%) 
0.02 
6 (30%) 39 (59%) 
0.005 
SCORES 0% 0 0 0 0 
1% -37% 0 1 (3%) 0 1 (2%) 
38% - 74% 3 (9%) 2 (6%) 6 (30%) 5 (8%) 
P-value 
75% -100% 30 (91%) 30 (91%) 14 (70%) 60 (91%) 
0.052 
SCORE3A 0% 0 0 0 0 
1% -37% 0 0 0 0 
38% - 74% 4 (12%) 1 (3%) 2 (10%) 5 (8%) 
P-value 
75% -100% 29 (88%) 32 (97%) 18 (90%) 61 (92%) 
SCORE4 0% 0 0 0 0 
1%-37% 0 0 1 (5%) 0 
38% - 74% 12 (36%) 6 (18%) 13 (65%) 18(27%) 
P-value 
75% -100% 21 (64%) 27 (82%) 
0.001 
6 (30%) 48 (73%) 
0.001 
SCORE4A 0% 0 0 0 0 
1 % - 37% 0 0 0 0 
38% - 74% 13 (39%) 4 (12%) 7 (35%) 17 (26%) 
P-value 
75%-100% 20 (61%) 29 (88%) 
0.04 
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Table 10 - Skin Self-Examination of 
Different Body Zones. 
PLC CONTROL p-value 









































1 Defined to be from three times per year to once a month 
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